salicylic acid has been researched along with Pruritus in 66 studies
Scalp: The outer covering of the calvaria. It is composed of several layers: SKIN; subcutaneous connective tissue; the occipitofrontal muscle which includes the tendinous galea aponeurotica; loose connective tissue; and the pericranium (the PERIOSTEUM of the SKULL).
Pruritus: An intense itching sensation that produces the urge to rub or scratch the skin to obtain relief.
Excerpt | Relevance | Reference |
---|---|---|
"A proprietary topical blend of salicylic acid and highly purified sandalwood oil from Australia was used in this open-label study in adolescents and adults with mild to moderate facial acne." | 9.16 | Single-center, open-label study of a proprietary topical 0.5% salicylic acid-based treatment regimen containing sandalwood oil in adolescents and adults with mild to moderate acne. ( Levenson, C; Moy, RL; Rock, JA; So, JJ, 2012) |
"To compare lipohydroxyacid and salicylic acid peels in subjects with comedonal acne." | 9.15 | Randomized trial comparing a chemical peel containing a lipophilic hydroxy acid derivative of salicylic acid with a salicylic acid peel in subjects with comedonal acne. ( Bissonnette, R; Hamzavi, I; Levesque, A; Rougier, A; Seite, S, 2011) |
"Clinical trials have demonstrated the efficacy of fixed-dose combination calcipotriol/betamethasone (Cal/BD) aerosol foam for the treatment of patients with scalp psoriasis." | 8.31 | Prospective Observational Evaluation of Fixed Combination Calcipotriol/Betamethasone Aerosol Foam (Enstilar®) in the Management of Psoriasis with Scalp Involvement in Everyday Clinical Practice (the CAPITIS Study). ( Hutt, HJ; Staubach, P; von Kiedrowski, R; Wurzer, E, 2023) |
"Due to the actives urea, lactate, polidocanol, and the anti-inflammatory licochalcone A, the new scalp tonic exhibited excellent performance in alleviating scalp dryness, itching, microinflammation, and in normalizing disturbances of scalp lipids." | 5.17 | Efficacy of a new tonic containing urea, lactate, polidocanol, and glycyrrhiza inflata root extract in the treatment of a dry, itchy, and subclinically inflamed scalp. ( Baufeld, C; Drescher, P; Filbry, A; Höpfner, S; Lüttke, J; Max, H; Mess, A; Oltrogge, B; Rippke, F; Schweiger, D, 2013) |
"A proprietary topical blend of salicylic acid and highly purified sandalwood oil from Australia was used in this open-label study in adolescents and adults with mild to moderate facial acne." | 5.16 | Single-center, open-label study of a proprietary topical 0.5% salicylic acid-based treatment regimen containing sandalwood oil in adolescents and adults with mild to moderate acne. ( Levenson, C; Moy, RL; Rock, JA; So, JJ, 2012) |
"To compare lipohydroxyacid and salicylic acid peels in subjects with comedonal acne." | 5.15 | Randomized trial comparing a chemical peel containing a lipophilic hydroxy acid derivative of salicylic acid with a salicylic acid peel in subjects with comedonal acne. ( Bissonnette, R; Hamzavi, I; Levesque, A; Rougier, A; Seite, S, 2011) |
"Clinical trials have demonstrated the efficacy of fixed-dose combination calcipotriol/betamethasone (Cal/BD) aerosol foam for the treatment of patients with scalp psoriasis." | 4.31 | Prospective Observational Evaluation of Fixed Combination Calcipotriol/Betamethasone Aerosol Foam (Enstilar®) in the Management of Psoriasis with Scalp Involvement in Everyday Clinical Practice (the CAPITIS Study). ( Hutt, HJ; Staubach, P; von Kiedrowski, R; Wurzer, E, 2023) |
"Despite the high prevalence of pruritus, scalp skin is less sensitive to histamine-induced experimental itching." | 3.71 | Sensitivity of human scalp skin to pruritic stimuli investigated by intradermal microdialysis in vivo. ( McGlone, F; Rukwied, R; Schmelz, M; Zeck, S, 2002) |
" Adverse events were predominantly mild or moderate." | 2.84 | Safety and Efficacy of Escalating Doses of Ingenol Mebutate for Field Treatment of Actinic Keratosis on the Full Face, Full Balding Scalp, or Chest. ( Berman, B; Bukhalo, M; Hanke, CW; Pariser, DM; Siegel, D; Skov, T; Swanson, N; Villumsen, J; Weiss, JS, 2017) |
"Scalp dysesthesia is an abnormal sensation of the scalp in the absence of cutaneous disease." | 2.82 | Scalp dysesthesia: a neuropathic phenomenon. ( Ju, T; Vander Does, A; Yosipovitch, G, 2022) |
" Safety was assessed according to the evaluations of trained observers and adverse event (AE) reports." | 2.78 | Assessment of the safety and efficacy of three concentrations of topical ivermectin lotion as a treatment for head lice infestation. ( Bell, M; Meinking, TL; Mertz-Rivera, K; Villar, ME, 2013) |
"Histamine levels were assessed in two groups of subjects with dandruff before and after 3 weeks of treatment with a commercial potentiated zinc pyrithione shampoo." | 2.76 | Scalp stratum corneum histamine levels: novel sampling method reveals association with itch resolution in dandruff/seborrhoeic dermatitis treatment. ( Fieno, A; Filloon, T; Kerr, K; Mills, KJ; Schwartz, JR; Szepietowski, JC; Wehmeyer, K, 2011) |
"Scalp pruritus is a frequent problem encountered in dermatological practice." | 2.61 | Scalp Pruritus: Review of the Pathogenesis, Diagnosis, and Management. ( Rattanakaemakorn, P; Suchonwanit, P, 2019) |
"There are multiple types of dysesthesias depending on the body location and the nerves involved." | 2.53 | Neurocutaneous disease: Neurocutaneous dysesthesias. ( Cole, E; Fernandez, KH; Shumway, NK, 2016) |
"Scalp pruritus is a common complaint that is considered a diagnostically and therapeutically challenging situation." | 2.47 | The itchy scalp--scratching for an explanation. ( Bin Saif, GA; Ericson, ME; Yosipovitch, G, 2011) |
"Scalp involvement and hair loss have not been reported among cutaneous changes associated with collagen VI mutations." | 1.91 | Alopecia in Patients with Collagen VI-Related Myopathies: A Novel/Unrecognized Scalp Phenotype. ( Baraldi, C; Bruni, F; Cedirian, S; Di Martino, A; Merlini, L; Misciali, C; Pampaloni, F; Piraccini, BM; Quadrelli, F; Sabatelli, P; Starace, M, 2023) |
"Pruritus is the sensation of itching; it can be caused by dermatologic and systemic conditions." | 1.72 | Pruritus: Diagnosis and Management. ( Honeycutt, JD; Rupert, J, 2022) |
"Scalp pruritus is a common skin problem that remains therapeutic challenge." | 1.72 | Microbiota profiling on itchy scalp with undetermined origin. ( Chang, X; Li, X; Shi, Y; Yan, H; Yang, F; Zhang, M; Zhang, Y, 2022) |
"Scalp dysesthesia is characterised by abnormal cutaneous sensations such as burning, stinging or itching of the scalp in the absence of objective dermatological findings." | 1.48 | Treatment of scalp dysesthesia utilising simple exercises and stretches: A pilot study. ( Chan, J; Laidler, NK, 2018) |
" In conclusion, superficial cryotherapy is an effective and safe therapeutic modality for AA." | 1.46 | Efficacy and safety of superficial cryotherapy for alopecia areata: A retrospective, comprehensive review of 353 cases over 22 years. ( Jun, M; Lee, NR; Lee, WS, 2017) |
"Eighteen patients with seborrheic dermatitis or psoriasis vulgaris scalp eruptions were instructed in proper techniques of daily hair washing, rinsing, and shampooing, which they underwent for 12 weeks." | 1.43 | Physiological and microbiological verification of the benefit of hair washing in patients with skin conditions of the scalp. ( Ito, K; Kobayashi, M; Matsunaka, H; Murakami, Y; Nakamura, M; Sugita, T; Yamashita, R, 2016) |
"A diagnosis of type IV delayed hypersensitivity reaction was made." | 1.40 | Severe facial swelling in a pregnant woman after using hair dye. ( Carels, G; Dees, A; Lonnee, ER; van Genderen, ME, 2014) |
"The diagnosis of an eosinophilic arteritis of the scalp may only be considered if the examination of the other peripheral vessels is normal and if the course of the disease is benign, without any treatment, in spite of a persistent blood eosinophilia." | 1.31 | [Eosinophilic arteritis of the scalp]. ( Asch, PH; Grosshans, E, 2001) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 9 (13.64) | 18.7374 |
1990's | 2 (3.03) | 18.2507 |
2000's | 8 (12.12) | 29.6817 |
2010's | 33 (50.00) | 24.3611 |
2020's | 14 (21.21) | 2.80 |
Authors | Studies |
---|---|
Massiot, P | 1 |
Reygagne, P | 1 |
Chagnoleau, C | 1 |
Kanoun-Copy, L | 1 |
Pouradier, F | 1 |
Loussouarn, G | 1 |
Queille-Roussel, C | 1 |
Jouni, H | 1 |
Kerob, D | 1 |
Patel, T | 1 |
Yosipovitch, G | 5 |
Levesque, A | 1 |
Hamzavi, I | 1 |
Seite, S | 1 |
Rougier, A | 1 |
Bissonnette, R | 1 |
Moy, RL | 1 |
Levenson, C | 1 |
So, JJ | 1 |
Rock, JA | 1 |
Thomsen, JS | 1 |
Simonsen, L | 1 |
Benfeldt, E | 1 |
Jensen, SB | 1 |
Serup, J | 1 |
PERLMAN, HH | 1 |
MEYER ZU SCHWEICHELN, H | 1 |
Thaçi, D | 1 |
Daiber, W | 1 |
Boehncke, WH | 1 |
Kaufmann, R | 1 |
Rupert, J | 1 |
Honeycutt, JD | 1 |
Ju, T | 1 |
Vander Does, A | 1 |
Martin, E | 1 |
Zhang, A | 1 |
Campiche, R | 1 |
Kang, SY | 1 |
Choi, MG | 1 |
Wei, ET | 1 |
Selescu, T | 1 |
Lee, SY | 1 |
Kim, JC | 1 |
Chung, BY | 1 |
Park, CW | 1 |
Kim, HO | 1 |
Kaliyadan, F | 1 |
Jayasree, P | 1 |
Ashique, KT | 1 |
Li, X | 1 |
Yang, F | 1 |
Yan, H | 1 |
Shi, Y | 1 |
Chang, X | 1 |
Zhang, M | 2 |
Zhang, Y | 1 |
Staubach, P | 1 |
Wurzer, E | 1 |
Hutt, HJ | 1 |
von Kiedrowski, R | 1 |
Yao, B | 1 |
Yue, X | 1 |
Liu, G | 1 |
de Jesus, GFA | 1 |
Rossetto, MP | 1 |
Voytena, A | 1 |
Feder, B | 1 |
Borges, H | 1 |
da Costa Borges, G | 1 |
Feuser, ZP | 1 |
Dal-Bó, S | 1 |
Michels, M | 1 |
Nattkemper, LA | 1 |
Lipman, ZM | 1 |
Ingrasci, G | 1 |
Maldonado, C | 1 |
Garces, JC | 1 |
Loayza, E | 1 |
Starace, M | 1 |
Pampaloni, F | 1 |
Bruni, F | 1 |
Quadrelli, F | 1 |
Cedirian, S | 1 |
Baraldi, C | 1 |
Misciali, C | 1 |
Di Martino, A | 1 |
Sabatelli, P | 1 |
Merlini, L | 1 |
Piraccini, BM | 1 |
Andersen, PL | 1 |
Jemec, GB | 1 |
Arendrup, MC | 1 |
Saunte, DM | 1 |
Bucko, AD | 1 |
Jarratt, M | 1 |
Stough, DB | 1 |
Kyhl, L | 1 |
Villumsen, J | 2 |
Hall, A | 1 |
Hanke, CW | 2 |
Berman, B | 1 |
Swanson, N | 1 |
Pariser, DM | 1 |
Weiss, JS | 1 |
Bukhalo, M | 1 |
Skov, T | 1 |
Siegel, D | 1 |
Feldman, SR | 1 |
Green, L | 1 |
Kimball, AB | 1 |
Siu, K | 1 |
Zhao, Y | 1 |
Herrera, V | 1 |
Nyirady, J | 1 |
Alexis, AF | 1 |
Xie, Y | 1 |
Zhang, Q | 1 |
Wang, L | 1 |
Laidler, NK | 1 |
Chan, J | 1 |
Nakamura, Y | 1 |
Saito, A | 1 |
Takamuki, R | 1 |
Inoue, S | 1 |
Fujisawa, Y | 1 |
Okiyama, N | 1 |
Watanabe, R | 1 |
Ishitsuka, Y | 1 |
Maruyama, H | 1 |
Ishii, Y | 1 |
Fujimoto, M | 1 |
Abdel-Rahman, Z | 1 |
Inamdar, K | 1 |
Ali, H | 1 |
Wang, Y | 1 |
Coyne, K | 1 |
Sofen, H | 1 |
Santanello, N | 1 |
Currie, B | 1 |
Zhang, Z | 1 |
Nograles, K | 1 |
Rattanakaemakorn, P | 1 |
Suchonwanit, P | 1 |
Charlton, D | 1 |
Moghadam-Kia, S | 1 |
Smith, K | 1 |
Aggarwal, R | 1 |
English, JC | 1 |
Oddis, CV | 1 |
Park, KH | 1 |
Kim, J | 1 |
Oh, B | 1 |
Lee, E | 1 |
Hwang-Bo, J | 1 |
Ha, J | 1 |
Schweiger, D | 1 |
Baufeld, C | 1 |
Drescher, P | 1 |
Oltrogge, B | 1 |
Höpfner, S | 1 |
Mess, A | 1 |
Lüttke, J | 1 |
Rippke, F | 1 |
Filbry, A | 1 |
Max, H | 1 |
Sarifakioglu, E | 1 |
Onur, O | 1 |
Yamakoshi, T | 1 |
Andoh, T | 1 |
Makino, T | 1 |
Kuraishi, Y | 1 |
Shimizu, T | 1 |
van Genderen, ME | 1 |
Carels, G | 1 |
Lonnee, ER | 1 |
Dees, A | 1 |
Dolohanty, LB | 1 |
Richardson, SJ | 1 |
Herrmann, DN | 1 |
Markman, J | 1 |
Mercurio, MG | 1 |
Kronborg, C | 1 |
Mahar, P | 1 |
Howard, A | 1 |
McCrary, WJ | 1 |
Hurst, MD | 1 |
Hiatt, KM | 1 |
Singh, ZN | 1 |
Wirges, ML | 1 |
Gonul, M | 1 |
Benar, H | 1 |
Gokce, A | 1 |
Shumway, NK | 1 |
Cole, E | 1 |
Fernandez, KH | 1 |
Lynch, MC | 1 |
Milchak, MA | 1 |
Parnes, H | 1 |
Ioffreda, MD | 1 |
Kobayashi, M | 1 |
Ito, K | 1 |
Sugita, T | 1 |
Murakami, Y | 1 |
Yamashita, R | 1 |
Matsunaka, H | 1 |
Nakamura, M | 1 |
Jun, M | 1 |
Lee, NR | 1 |
Lee, WS | 1 |
Chitgopeker, P | 1 |
Lehrer, M | 1 |
Landherr, MJ | 1 |
Liu, V | 1 |
Bernhard, JD | 1 |
Samrao, A | 1 |
Chew, AL | 1 |
Price, V | 1 |
Kerr, K | 1 |
Schwartz, JR | 1 |
Filloon, T | 1 |
Fieno, A | 1 |
Wehmeyer, K | 1 |
Szepietowski, JC | 1 |
Mills, KJ | 1 |
Bin Saif, GA | 2 |
Ericson, ME | 1 |
Alajroush, A | 1 |
McMichael, A | 1 |
Kwatra, SG | 1 |
Chan, YH | 1 |
McGlone, F | 2 |
Takcı, Z | 1 |
Tekin, O | 1 |
Karadağ, AS | 1 |
Meinking, TL | 1 |
Mertz-Rivera, K | 1 |
Villar, ME | 1 |
Bell, M | 1 |
Harding, CR | 1 |
Moore, AE | 1 |
Rogers, JS | 1 |
Meldrum, H | 1 |
Scott, AE | 1 |
McGlone, FP | 1 |
Rukwied, R | 1 |
Zeck, S | 1 |
Schmelz, M | 1 |
Piérard-Franchimont, C | 1 |
Piérard, GE | 1 |
Guarneri, F | 1 |
Guarneri, C | 1 |
Mento, G | 1 |
Ioli, A | 1 |
Fallah, H | 1 |
Dunlop, K | 1 |
Kossard, S | 1 |
Jorizzo, JL | 1 |
Brenner, S | 1 |
Ophir, J | 1 |
Krakowski, A | 1 |
Bergfeld, WF | 1 |
Rauscher, GE | 1 |
DiGregorio, VR | 1 |
van de Kerkhof, PC | 1 |
de Hoop, D | 1 |
de Korte, J | 1 |
Kuipers, MV | 1 |
Moon, CM | 1 |
Schissel, DJ | 1 |
Grosshans, E | 1 |
Asch, PH | 1 |
Scribner, M | 1 |
Vinas, JC | 1 |
Caviglia, C | 1 |
Cortinas, JL | 1 |
Harris, JJ | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
A Phase 2B, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate-to-Severe Plaque-Type Psoriasis (Core Study)[NCT00773734] | Phase 2 | 352 participants (Actual) | Interventional | 2008-09-01 | Completed | ||
A Phase 3, Multi-Center, Randomized, Placebo-Controlled, Double-Blind, Study of the Efficacy and Safety of Apremilast (CC-10004) in Subjects With Moderate to Severe Plaque Psoriasis of the Scalp[NCT03123471] | Phase 3 | 303 participants (Actual) | Interventional | 2017-05-16 | Completed | ||
Treatment Results for Patients With Central Centrifugal Cicatricial Alopecia (CCCA): a Multicenter Prospective Study[NCT04207931] | Phase 4 | 250 participants (Anticipated) | Interventional | 2018-04-30 | Recruiting | ||
A Double-Blind, Placebo-Controlled Study Comparing the Safety and Efficacy of 3 Strengths of Ivermectin Treatment Conditioner and Placebo in Subjects With Pediculus Humanus Capitis (Head Lice) Infestation[NCT00857948] | Phase 2 | 78 participants (Actual) | Interventional | 2009-03-31 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Area under the concentration versus time curve from time 0 (pre-dose) to 8 hours, calculate using the linear trapezoid rule. (NCT00773734)
Timeframe: Week 24
Intervention | ng*h/mL (Geometric Mean) |
---|---|
Apremilast 10mg | 1200 |
Apremilast 20mg | 1257 |
Apremilast 30 mg | 3477 |
Area under the concentration versus time curve from time 0 (pre-dose) to 8 hours, calculated using the linear trapezoid rule. (NCT00773734)
Timeframe: Week 14; Predose, 0.5, 1, 2, 3, 4, and 8 hours after the morning dose of apremilast
Intervention | ng*h/mL (Geometric Mean) |
---|---|
Apremilast 10mg BID | 1008 |
Apremilast 20mg BID | 1591 |
Apremilast 30 mg BID | 3467 |
The DLQI was a validated, self-administered, 10-item questionnaire that measures the impact of skin disease on subjects' quality of life, based on recall over the past week. Domains include symptoms, feelings, daily activities, social, leisure, work or studying, personal relationships and treatment. Each question on the extent of the impact of skin disease was answered on a scale of 0 (not at all) to 3 (very much); the total DLQI score ranged from 0 to 30. A DLQI score greater than 10 is indicative of severe psoriasis. (NCT00773734)
Timeframe: Week 0 to Week 16
Intervention | units on a scale (Least Squares Mean) |
---|---|
Placebo BID | -1.9 |
Apremilast 10mg BID | -3.2 |
Apremilast 20mg BID | -5.9 |
Apremilast 30 mg BID | -4.4 |
The DLQI was a validated, self-administered, 10-item questionnaire that measures the impact of skin disease on subjects' quality of life, based on recall over the past week. Domains include symptoms, feelings, daily activities, social, leisure, work or studying, personal relationships and treatment. Each question on the extent of the impact of skin disease was answered on a scale of 0 (not at all) to 3 (very much); the total DLQI score ranged from 0 to 30. A DLQI score greater than 10 is indicative of severe psoriasis. (NCT00773734)
Timeframe: Week 0 to Week 24
Intervention | units on a scale (Mean) |
---|---|
Apremilast 10mg BID | -3.4 |
Apremilast 20mg BID | -6.2 |
Apremilast 30 mg BID | -4.9 |
Placebo-Apremilast (APR) 20 mg BID | -6.4 |
Placebo-Apremilast 30 mg BID | -5.4 |
The SF-36 was a 36-item general health status instrument and consists of 8 scales: physical function (PF), role limitations-physical (RP), vitality (VT), general health perceptions (GH), bodily pain (BP), social function (SF), role limitations-emotional (RE), and mental health (MH). Scale scores range from 0 to 100, with higher scores indicating better health. Two overall summary scores were obtained - a Physical Component Summary score (PCS) and a Mental Component Summary score (MCS). Scores from the 8 scales, PCS and MCS were transformed to the norm-based scores using weights from U.S. general population, with 50 as the average and 10 as the standard deviation, higher scores indicating better health. For norm based scores, change from baseline were calculated for the 8 scales and the two summary scales, where change = visit value - baseline value. (NCT00773734)
Timeframe: Week 0 to Week 24
Intervention | units on a scale (Mean) |
---|---|
Apremilast 10mg BID | 1.1 |
Apremilast 20mg BID | 2.3 |
Apremilast 30 mg BID | 1.0 |
PBO-Apremilast 20mg BID | 2.5 |
PBO-Apremilast 30 mg BID | 2.7 |
The SF-36 was a 36-item general health status instrument and consists of 8 scales: physical function (PF), role limitations-physical (RP), vitality (VT), general health perceptions (GH), bodily pain (BP), social function (SF), role limitations-emotional (RE), and mental health (MH). Scale scores range from 0 to 100, with higher scores indicating better health. Two overall summary scores were obtained - a Physical Component Summary score (PCS) and a Mental Component Summary score (MCS). Scores from the 8 scales, PCS and MCS were transformed to the norm-based scores using weights from U.S. general population, with 50 as the average and 10 as the standard deviation, higher scores indicating better health. For norm based scores, change from baseline were calculated for the 8 scales and the two summary scales, where change = visit value - baseline value. (NCT00773734)
Timeframe: Week 0 to Week 16
Intervention | units on a scale (Least Squares Mean) |
---|---|
Placebo BID | -0.6 |
Apremilast 10mg BID | 2.8 |
Apremilast 20mg BID | 2.9 |
Apremilast 30 mg BID | 3.0 |
The SF-36 was a 36-item general health status instrument and consists of 8 scales: physical function (PF), role limitations-physical (RP), vitality (VT), general health perceptions (GH), bodily pain (BP), social function (SF), role limitations-emotional (RE), and mental health (MH). Scale scores range from 0 to 100, with higher scores indicating better health. Two overall summary scores were obtained - a Physical Component Summary score (PCS) and a Mental Component Summary score (MCS). Scores from the 8 scales, PCS and MCS were transformed to the norm-based scores using weights from U.S. general population, with 50 as the average and 10 as the standard deviation, higher scores indicating better health. For norm based scores, change from baseline were calculated for the 8 scales and the two summary scales, where change = visit value - baseline value. (NCT00773734)
Timeframe: Week 0 to Week 24
Intervention | units on a scale (Mean) |
---|---|
Apremilast 10mg BID | 2.8 |
Apremilast 20mg BID | 3.9 |
Apremilast 30 mg BID | 2.9 |
PBO-Apremilast 20mg BID | 2.8 |
PBO-Apremilast 30 mg BID | 0.5 |
The SF-36 was a 36-item general health status instrument and consists of 8 scales: physical function (PF), role limitations-physical (RP), vitality (VT), general health perceptions (GH), bodily pain (BP), social function (SF), role limitations-emotional (RE), and mental health (MH). Scale scores range from 0 to 100, with higher scores indicating better health. Two overall summary scores were obtained - a Physical Component Summary score (PCS) and a Mental Component Summary score (MCS). Scores from the 8 scales, PCS and MCS were transformed to the norm-based scores using weights from U.S. general population, with 50 as the average and 10 as the standard deviation, higher scores indicating better health. For norm based scores, change from baseline were calculated for the 8 scales and the two summary scales, where change = visit value - baseline value. (NCT00773734)
Timeframe: Week 0 to week 16
Intervention | units on a scale (Least Squares Mean) |
---|---|
Placebo BID | 0.7 |
Apremilast 10mg BID | 1.3 |
Apremilast 20mg BID | 2.1 |
Apremilast 30 mg BID | 0.8 |
The maximum observed plasma concentration of apremilast observed at Week 14 (steady-state Cmax) (NCT00773734)
Timeframe: Week 14; Predose, 0.5, 1, 2, 3, 4, and 8 hours after the morning dose of apremilast
Intervention | ng/mL (Geometric Mean) |
---|---|
Apremilast 10mg BID | 209 |
Apremilast 20mg BID | 298 |
Apremilast 30 mg BID | 637 |
The maximum observed plasma concentration of apremilast observed at Week 24 (steady-state Cmax) (NCT00773734)
Timeframe: Week 24
Intervention | ng/mL (Geometric Mean) |
---|---|
Apremilast 10mg BID | 238 |
Apremilast 20mg BID | 236 |
Apremilast 30 mg BID | 670 |
The PASI was a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness, and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling were scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions was scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). The total qualitative score (sum of erythema, thickness, and scaling scores) was multiplied by the degree of involvement for each anatomic region and then multiplied by a constant. The values for each anatomic region were summed to yield the PASI score. (NCT00773734)
Timeframe: Week 0 to Week 16
Intervention | Percent change (Least Squares Mean) |
---|---|
Placebo BID | -20.3 |
Apremilast 10mg BID | -34.0 |
Apremilast 20mg BID | -45.4 |
Apremilast 30 mg BID | -53.2 |
The PASI is a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness, and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling were scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions was scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). The total qualitative score (sum of erythema, thickness, and scaling scores) was multiplied by the degree of involvement for each anatomic region and then multiplied by a constant. The values for each anatomic region were summed to yield the PASI score (NCT00773734)
Timeframe: Week 0 to Week 24
Intervention | percent change (Mean) |
---|---|
Apremilast 10mg BID | -36.3 |
Apremilast 20mg BID | -46.5 |
Apremilast 30 mg BID | -56.8 |
PBO-Apremilast 20mg BID | -61.7 |
PBO-Apremilast 30 mg BID | -61.7 |
"The overall BSA affected by psoriasis was estimated by comparison of the size of the affected area to the palm area of the participant's hand (entire palmar surface or handprint), which equates to approximately 1% of total BSA." (NCT00773734)
Timeframe: Week 0 to Week 24
Intervention | percent change (Mean) |
---|---|
Apremilast 10mg BID | -28.1 |
Apremilast 20mg BID | -40.6 |
Apremilast 30 mg BID | -54.0 |
Placebo-Apremilast 20 mg BID | -52.5 |
Placebo-Apremilast 30 mg BID | -54.2 |
"The overall BSA affected by psoriasis was estimated by comparison of the size of the affected area to the palm area of the participant's hand (entire palmar surface or handprint), which equates to approximately 1% of total BSA." (NCT00773734)
Timeframe: Week 0 to Week 16
Intervention | percent change (Least Squares Mean) |
---|---|
Placebo BID | -8.0 |
Apremilast 10mg BID | -28.3 |
Apremilast 20mg BID | -38.0 |
Apremilast 30 mg BID | -50.4 |
PASI-50 response is the percentage of participants who achieved at least a 50% reduction (improvement) from baseline in PASI score at Week 16. The improvement in PASI score was used as a measure of efficacy The PASI score was a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness, and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). (NCT00773734)
Timeframe: Week 0 to Week 16
Intervention | percentage of participants (Number) |
---|---|
Placebo BID | 25.0 |
Apremilast 10mg BID | 38.2 |
Apremilast 20mg BID | 47.1 |
Apremilast 30 mg BID | 60.2 |
PASI-50 response is the percentage of participants who achieved at least a 50% reduction (improvement) from baseline in PASI score at Week 24. The improvement in PASI score was used as a measure of efficacy. The PASI score was a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness, and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). (NCT00773734)
Timeframe: Week 0 to Week 24
Intervention | percentage of participants (Number) |
---|---|
Apremilast 10mg BID | 38.2 |
Apremilast 20mg | 49.4 |
Apremilast 30 mg BID | 65.9 |
Placebo-Apremilast 20mg BID | 61.8 |
PBO-Apremilast 30 mg BID | 75.0 |
PASI-75 response is the percentage of participants who achieved at least a 75% reduction (improvement) from baseline in PASI score at Week 24. The improvement in PASI score was used as a measure of efficacy.The PASI was a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head,trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). (NCT00773734)
Timeframe: Week 0 to Week 24
Intervention | percentage of participants (Number) |
---|---|
Apremilast 10mg BID | 18.0 |
Apremilast 20mg BID | 26.4 |
Apremilast 30 mg BID | 39.8 |
PBO-Apremilast 20mg BID | 41.2 |
PBO-Apremilast 30 mg BID | 44.4 |
PASI-75 response is the percentage of participants who achieved at least a 75% reduction (improvement) from baseline in PASI score at Week 16. The improvement in PASI score was used as a measure of efficacy. The PASI was a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). (NCT00773734)
Timeframe: Week 0 and Week 16
Intervention | percentage of participants (Number) |
---|---|
Placebo BID | 5.7 |
Apremilast 10mg BID | 11.2 |
Apremilast 20mg BID | 28.7 |
Apremilast 30 mg BID | 40.9 |
PASI-90 response is the percentage of participants who achieved at least a 90% reduction (improvement) from baseline in PASI score at Week 16. The improvement in PASI score was used as a measure of efficacy. The PASI score was a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness, and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). (NCT00773734)
Timeframe: Week 0 to Week 16
Intervention | percentage of participants (Number) |
---|---|
Placebo BID | 1.1 |
Apremilast 10mg BID | 4.5 |
Apremilast 20mg BID | 9.2 |
Apremilast 30 mg BID | 11.4 |
PASI-90 response is the percentage of participants who achieved at least a 90% reduction (improvement) from baseline in PASI score at Week 24. The improvement in PASI score was used as a measure of efficacy..The PASI is a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness, and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling were scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions was scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). (NCT00773734)
Timeframe: Week 0 to Week 24
Intervention | percentage of participants (Number) |
---|---|
Apremilast 10mg | 4.5 |
Apremilast 20mg | 8.0 |
Apremilast 30 mg | 14.8 |
PBO-Apremilast 20mg BID | 14.7 |
Placebo-Apremilast 30 mg BID | 16.7 |
The sPGA was a measure of psoriasis disease severity at the time of evaluation by the investigator. It does not compare assessments across visits or rely on investigator recall of prior disease severity. The sPGA was a 6-point scale ranging from 0 (clear, except for residual discoloration) to 5 (severe; majority of plaques have severe thickness, erythema, and scaling). The investigator examined all of the lesions on the participant and assigned a score ranging from 0 to 5 for thickness, erythema and degree of scaling . Scores for thickness, erythema and scaling are then summed and the mean of these 3 scores equaled the overall sPGA score. Fractional values for the sPGA were rounded to the next highest integer (eg, a score of 3.5 was rounded to 4, 3.4 was rounded to 3). A lower sPGA score was associated with less severe disease (NCT00773734)
Timeframe: Week 0 and Week 24
Intervention | percentage of participants (Number) |
---|---|
Apremilast 10mg BID | 13.5 |
Apremilast 20mg BID | 24.1 |
Apremilast 30 mg BID | 34.1 |
Placebo-Apremilast 20 mg BID | 41.2 |
Placebo-Apremilast 30 mg BID | 50.0 |
The sPGA was a measure of psoriasis disease severity at the time of evaluation by the investigator. It does not compare assessments across visits or rely on investigator recall of prior disease severity. The sPGA was a 6-point scale ranging from 0 (clear, except for residual discoloration) to 5 (severe; majority of plaques have severe thickness, erythema, and scaling). The investigator examined all of the lesions on the participant and assigned a score ranging from 0 to 5 for thickness, erythema and degree of scaling . Scores for thickness, erythema and scaling are then summed and the mean of these 3 scores equaled the overall sPGA score. Fractional values for the sPGA were rounded to the next highest integer (eg, a score of 3.5 was rounded to 4, 3.4 was rounded to 3). A lower sPGA score was associated with less severe disease (NCT00773734)
Timeframe: Week 0 to Week 16
Intervention | percentage of participants (Number) |
---|---|
Placebo | 12.6 |
Apremilast 10mg | 10.5 |
Apremilast 20mg | 25.0 |
Apremilast 30 mg | 33.7 |
For PASI-50 responders in the placebo-controlled period weeks 0-16, time to achieve PASI-50 was defined as the time interval, inclusive between the date of randomization (day 1) and the date of the first assessment where PASI-50 was achieved. (NCT00773734)
Timeframe: Week 0 to 16
Intervention | weeks (Median) |
---|---|
Placebo BID | 6.5 |
Apremilast 10mg BID | 5.9 |
Apremilast 20mg BID | 6.0 |
Apremilast 30 mg BID | 4.3 |
For PASI-75 responders in the placebo-controlled period Weeks 0-16, time to achieve PASI-75 was defined as the time interval, inclusive between the date of randomization (day 1) and the date of the first assessment where PASI-75 is achieved. (NCT00773734)
Timeframe: Weeks 0 to 16
Intervention | weeks (Median) |
---|---|
Placebo BID | 8.1 |
Apremilast 10mg BID | 10.0 |
Apremilast 20mg BID | 11.9 |
Apremilast 30 mg BID | 6.3 |
Time to achieve maximum plasma concentration (Cmax) observed at Week 14 (Time to achieve steady-state Tmax) (NCT00773734)
Timeframe: Week 14; Predose, 0.5, 1, 2, 3, 4, and 8 hours after the morning dose of apremilast
Intervention | hours (Median) |
---|---|
Apremilast 10mg BID | 2.00 |
Apremilast 20mg BID | 2.00 |
Apremilast 30 mg BID | 1.00 |
Time to achieve maximum plasma concentration (tmax) observed at Week 24 (Time to achieve steady-state Tmax) (NCT00773734)
Timeframe: Week 24
Intervention | hours (Median) |
---|---|
Apremilast 10mg BID | 1.00 |
Apremilast 20mg BID | 1.50 |
Apremilast 30 mg BID | 1.00 |
The DLQI was a validated, self-administered, 10-item questionnaire that measures the impact of skin disease on subjects' quality of life, based on recall over the past week. Domains include symptoms, feelings, daily activities, social, leisure, work or studying, personal relationships and treatment. Each question on the extent of the impact of skin disease was answered on a scale of 0 (not at all) to 3 (very much); the total DLQI score ranged from 0 to 30. A DLQI score greater than 10 is indicative of severe psoriasis. (NCT00773734)
Timeframe: Week 0 to Week 32
Intervention | units on a scale (Mean) |
---|---|
Apremilast 10mg BID | -6.5 |
Apremilast 20mg BID | -7.5 |
Apremilast 30 mg BID | -6.0 |
Placebo-Apremilast 20mg BID | -8.1 |
Placebo-Apremilast 30 mg BID | 5.5 |
The DLQI was a validated, self-administered, 10-item questionnaire that measures the impact of skin disease on subjects' quality of life, based on recall over the past week. Domains include symptoms, feelings, daily activities, social, leisure, work or studying, personal relationships and treatment. Each question on the extent of the impact of skin disease was answered on a scale of 0 (not at all) to 3 (very much); the total DLQI score ranged from 0 to 30. A DLQI score greater than 10 is indicative of severe psoriasis. (NCT00773734)
Timeframe: Week 0 to Week 40
Intervention | units on a scale (Mean) |
---|---|
Apremilast 10mg BID | -5.5 |
Apremilast 20mg BID | -6.6 |
Apremilast 30 mg BID | -6.4 |
Placebo-Apremilast 20mg BID | -7.1 |
Placebo-Apremilast 30 mg BID | -5.9 |
The DLQI was a validated, self-administered, 10-item questionnaire that measures the impact of skin disease on subjects' quality of life, based on recall over the past week. Domains include symptoms, feelings, daily activities, social, leisure, work or studying, personal relationships and treatment. Each question on the extent of the impact of skin disease was answered on a scale of 0 (not at all) to 3 (very much); the total DLQI score ranged from 0 to 30. A DLQI score greater than 10 is indicative of severe psoriasis. (NCT00773734)
Timeframe: Week 0 to Week 52
Intervention | units on a scale (Mean) |
---|---|
Apremilast 10mg BID | -5.8 |
Apremilast 20mg BID | -6.1 |
Apremilast 30 mg BID | -5.6 |
Placebo-Apremilast 20mg BID | -6.8 |
Placebo-Apremilast 30 mg BID | -4.9 |
The SF-36 was a 36-item general health status instrument and consists of 8 scales: physical function (PF), role limitations-physical (RP), vitality (VT), general health perceptions (GH), bodily pain (BP), social function (SF), role limitations-emotional (RE), and mental health (MH). Scale scores range from 0 to 100, with higher scores indicating better health. Two overall summary scores were obtained - a Physical Component Summary score (PCS) and a Mental Component Summary score (MCS). Scores from the 8 scales, PCS and MCS were transformed to the norm-based scores using weights from U.S. general population, with 50 as the average and 10 as the standard deviation, higher scores indicating better health. For norm based scores, change from baseline were calculated for the 8 scales and the two summary scales, where change = visit value - baseline value. (NCT00773734)
Timeframe: Week 0 to Week 40
Intervention | units on a scale (Mean) |
---|---|
Apremilast 10mg BID | -0.2 |
Apremilast 20mg BID | 1.6 |
Apremilast 30 mg BID | 1.7 |
Placebo-Apremilast 20mg BID | 3.2 |
Placebo-Apremilast 30 mg BID | 1.8 |
The SF-36 was a 36-item general health status instrument and consists of 8 scales: physical function (PF), role limitations-physical (RP), vitality (VT), general health perceptions (GH), bodily pain (BP), social function (SF), role limitations-emotional (RE), and mental health (MH). Scale scores range from 0 to 100, with higher scores indicating better health. Two overall summary scores were obtained - a Physical Component Summary score (PCS) and a Mental Component Summary score (MCS). Scores from the 8 scales, PCS and MCS were transformed to the norm-based scores using weights from U.S. general population, with 50 as the average and 10 as the standard deviation, higher scores indicating better health. For norm based scores, change from baseline were calculated for the 8 scales and the two summary scales, where change = visit value - baseline value. (NCT00773734)
Timeframe: Week 0 to Week 32
Intervention | units on a scale (Mean) |
---|---|
Apremilast 10mg BID | 5.2 |
Apremilast 20mg BID | 3.8 |
Apremilast 30 mg BID | 2.9 |
Placebo-Apremilast 20mg BID | 4.6 |
Placebo-Apremilast 30 mg BID | 2.8 |
The SF-36 was a 36-item general health status instrument and consists of 8 scales: physical function (PF), role limitations-physical (RP), vitality (VT), general health perceptions (GH), bodily pain (BP), social function (SF), role limitations-emotional (RE), and mental health (MH). Scale scores range from 0 to 100, with higher scores indicating better health. Two overall summary scores were obtained - a Physical Component Summary score (PCS) and a Mental Component Summary score (MCS). Scores from the 8 scales, PCS and MCS were transformed to the norm-based scores using weights from U.S. general population, with 50 as the average and 10 as the standard deviation, higher scores indicating better health. For norm based scores, change from baseline were calculated for the 8 scales and the two summary scales, where change = visit value - baseline value. (NCT00773734)
Timeframe: Week 0 to Week 40
Intervention | units on a scale (Mean) |
---|---|
Apremilast 10mg BID | 5.4 |
Apremilast 20mg BID | 4.8 |
Apremilast 30 mg BID | 1.7 |
Placebo-Apremilast 20mg BID | 2.9 |
Placebo-Apremilast 30 mg BID | 3.8 |
The SF-36 was a 36-item general health status instrument and consists of 8 scales: physical function (PF), role limitations-physical (RP), vitality (VT), general health perceptions (GH), bodily pain (BP), social function (SF), role limitations-emotional (RE), and mental health (MH). Scale scores range from 0 to 100, with higher scores indicating better health. Two overall summary scores were obtained - a Physical Component Summary score (PCS) and a Mental Component Summary score (MCS). Scores from the 8 scales, PCS and MCS were transformed to the norm-based scores using weights from U.S. general population, with 50 as the average and 10 as the standard deviation, higher scores indicating better health. For norm based scores, change from baseline were calculated for the 8 scales and the two summary scales, where change = visit value - baseline value. (NCT00773734)
Timeframe: Week 0 to Week 52
Intervention | units on a scale (Mean) |
---|---|
Apremilast 10mg BID | 5.1 |
Apremilast 20mg BID | 4.1 |
Apremilast 30 mg BID | 2.4 |
Placebo-Apremilast 20mg BID | 4.7 |
Placebo-Apremilast 30 mg BID | 3.4 |
The SF-36 was a 36-item general health status instrument and consists of 8 scales: physical function (PF), role limitations-physical (RP), vitality (VT), general health perceptions (GH), bodily pain (BP), social function (SF), role limitations-emotional (RE), and mental health (MH). Scale scores range from 0 to 100, with higher scores indicating better health. Two overall summary scores were obtained - a Physical Component Summary score (PCS) and a Mental Component Summary score (MCS). Scores from the 8 scales, PCS and MCS were transformed to the norm-based scores using weights from U.S. general population, with 50 as the average and 10 as the standard deviation, higher scores indicating better health. For norm based scores, change from baseline were calculated for the 8 scales and the two summary scales, where change = visit value - baseline value. (NCT00773734)
Timeframe: Week 0 to Week 32
Intervention | units on a scale (Mean) |
---|---|
Apremilast 10mg BID | 1.4 |
Apremilast 20mg BID | 2.6 |
Apremilast 30 mg BID | 1.8 |
Placebo-Apremilast 20mg BID | 3.1 |
Placebo-Apremilast 30 mg BID | 1.5 |
The SF-36 was a 36-item general health status instrument and consists of 8 scales: physical function (PF), role limitations-physical (RP), vitality (VT), general health perceptions (GH), bodily pain (BP), social function (SF), role limitations-emotional (RE), and mental health (MH). Scale scores range from 0 to 100, with higher scores indicating better health. Two overall summary scores were obtained - a Physical Component Summary score (PCS) and a Mental Component Summary score (MCS). Scores from the 8 scales, PCS and MCS were transformed to the norm-based scores using weights from U.S. general population, with 50 as the average and 10 as the standard deviation, higher scores indicating better health. For norm based scores, change from baseline were calculated for the 8 scales and the two summary scales, where change = visit value - baseline value.. (NCT00773734)
Timeframe: Week 0 to Week 52
Intervention | units on a scale (Mean) |
---|---|
Apremilast 10mg BID | 1.2 |
Apremilast 20mg BID | 1.2 |
Apremilast 30 mg BID | 2.0 |
Placebo-Apremilast 20mg BID | 3.4 |
Placebo-Apremilast 30 mg BID | 0.3 |
"The overall BSA affected by psoriasis was estimated by comparison of the size of the affected area to the palm area of the participant's hand (entire palmar surface or handprint), which equates to approximately 1% of total BSA." (NCT00773734)
Timeframe: Week 0 to Week 32
Intervention | percent change (Mean) |
---|---|
Apremilast 10mg BID | -47.1 |
Apremilast 20mg BID | -65.1 |
Apremilast 30 mg BID | -75.3 |
Placebo-Apremilast 20mg BID | -62.6 |
Placebo-Apremilast 30 mg BID | -66.7 |
"The overall BSA affected by psoriasis was estimated by comparison of the size of the affected area to the palm area of the participant's hand (entire palmar surface or handprint), which equates to approximately 1% of total BSA." (NCT00773734)
Timeframe: Week 0 to Week 40
Intervention | percent change (Mean) |
---|---|
Apremilast 10mg BID | -55.4 |
Apremilast 20mg BID | -65.4 |
Apremilast 30 mg BID | -74.3 |
Placebo-Apremilast 20mg BID | -66.2 |
Placebo-Apremilast 30 mg BID | -68.0 |
"The overall BSA affected by psoriasis was estimated by comparison of the size of the affected area to the palm area of the participant's hand (entire palmar surface or handprint), which equates to approximately 1% of total BSA." (NCT00773734)
Timeframe: Week 0 to Week 52
Intervention | percent change (Mean) |
---|---|
Apremilast 10mg BID | -53.1 |
Apremilast 20mg BID | -58.3 |
Apremilast 30 mg BID | -67.3 |
Placebo-Apremilast 20mg BID | -67.4 |
Placebo-Apremilast 30 mg BID | -64.9 |
The PASI is a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness, and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling were scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions was scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). The total qualitative score (sum of erythema, thickness, and scaling scores) was multiplied by the degree of involvement for each anatomic region and then multiplied by a constant. The values for each anatomic region were summed to yield the PASI score (NCT00773734)
Timeframe: Week 0 to Week 32
Intervention | percent change (Mean) |
---|---|
Apremilast 10mg BID | -51.0 |
Apremilast 20mg BID | -63.1 |
Apremilast 30 mg BID | -72.7 |
Placebo-Apremilast 20mg BID | -64.0 |
Placebo-Apremilast 30 mg BID | -69.2 |
The PASI is a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness, and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling were scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions was scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). The total qualitative score (sum of erythema, thickness, and scaling scores) was multiplied by the degree of involvement for each anatomic region and then multiplied by a constant. The values for each anatomic region were summed to yield the PASI score (NCT00773734)
Timeframe: Week 0 to Week 40
Intervention | percent change (Mean) |
---|---|
Apremilast 10mg BID | -55.9 |
Apremilast 20mg BID | -63.3 |
Apremilast 30 mg BID | -71.1 |
Placebo-Apremilast 20mg BID | -64.5 |
Placebo-Apremilast 30 mg BID | -71.7 |
The PASI is a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness, and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling were scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions was scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). The total qualitative score (sum of erythema, thickness, and scaling scores) was multiplied by the degree of involvement for each anatomic region and then multiplied by a constant. The values for each anatomic region were summed to yield the PASI score (NCT00773734)
Timeframe: Week 0 to Week 52
Intervention | percent change (Mean) |
---|---|
Apremilast 10mg BID | -55.1 |
Apremilast 20mg BID | -58.9 |
Apremilast 30 mg BID | -65.3 |
Placebo-Apremilast 20mg BID | -62.7 |
Placebo-Apremilast 30 mg BID | -62.0 |
PASI-50 response is the percentage of participants who achieved at least a 50% reduction (improvement) from baseline in PASI score at Week 32 of the extension study. The improvement in PASI score was used as a measure of efficacy. The PASI was a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). (NCT00773734)
Timeframe: Week 0 to Week 32
Intervention | percentage of participants (Number) |
---|---|
Apremilast 10mg BID | 57.4 |
Apremilast 20mg BID | 72.0 |
Apremilast 30 mg BID | 86.2 |
Placebo-Apremilast 20mg BID | 74.1 |
Placebo-Apremilast 30 mg BID | 74.1 |
PASI-50 response is the percentage of participants who achieved at least a 50% reduction (improvement) from baseline in PASI score at Week 16 of the extension study. The improvement in PASI score was used as a measure of efficacy. The PASI was a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). (NCT00773734)
Timeframe: Week 0 to Week 40
Intervention | percentage of participants (Number) |
---|---|
Apremilast 10mg BID | 48.9 |
Apremilast 20mg BID | 62.0 |
Apremilast 30 mg BID | 82.8 |
Placebo-Apremilast 20mg BID | 63.0 |
Placebo-Apremilast 30 mg BID | 66.7 |
PASI-50 response is the percentage of participants who achieved at least a 50% reduction (improvement) from baseline in PASI score at Week 52 of the extension study. The improvement in PASI score was used as a measure of efficacy. The PASI was a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). (NCT00773734)
Timeframe: Week 0 to Week 52
Intervention | percentage of participants (Number) |
---|---|
Apremilast 10mg BID | 42.6 |
Apremilast 20mg BID | 48.0 |
Apremilast 30 mg BID | 72.4 |
Placebo-Apremilast 20mg BID | 55.6 |
Placebo-Apremilast 30 mg BID | 48.1 |
PASI-75 response is the percentage of participants who achieved at least a 75% reduction (improvement) from baseline in PASI score at Week 32 of the extension study. The improvement in PASI score was used as a measure of efficacy. The PASI was a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). (NCT00773734)
Timeframe: Week 0 to Week 32
Intervention | percentage of participants (Number) |
---|---|
Apremilast 10mg BID | 27.7 |
Apremilast 20mg BID | 38.0 |
Apremilast 30 mg BID | 46.6 |
Placebo-Apremilast 20mg BID | 33.3 |
Placebo-Apremilast 30 mg BID | 55.6 |
PASI-75 response is the percentage of participants who achieved at least a 75% reduction (improvement) from baseline in PASI score at Week 40 of the extension study. The improvement in PASI score was used as a measure of efficacy. The PASI was a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). (NCT00773734)
Timeframe: Week 0 to Week 40
Intervention | percentage of participants (Number) |
---|---|
Apremilast 10mg BID | 21.3 |
Apremilast 20mg BID | 28.0 |
Apremilast 30 mg BID | 34.5 |
Placebo-Apremilast 20mg BID | 37.0 |
Placebo-Apremilast 30 mg BID | 44.4 |
PASI-75 response is the percentage of participants who achieved at least a 75% reduction (improvement) from baseline in PASI score at Week 52. The improvement in PASI score was used as a measure of efficacy. The PASI was a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). (NCT00773734)
Timeframe: Week 0 to Week 52
Intervention | percentage of participants (Number) |
---|---|
Apremilast 10mg BID | 14.9 |
Apremilast 20mg BID | 22.0 |
Apremilast 30 mg BID | 36.2 |
Placebo-Apremilast 20mg BID | 37.0 |
Placebo-Apremilast 30 mg BID | 33.3 |
PASI-90 response is the percentage of participants who achieved at least a 90% reduction (improvement) from baseline in PASI score at Week 32 of the extension study. The improvement in PASI score was used as a measure of efficacy. The PASI was a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). (NCT00773734)
Timeframe: Week 0 to Week 32
Intervention | percentage of participants (Number) |
---|---|
Apremilast 10mg BID | 10.6 |
Apremilast 20mg BID | 14.0 |
Apremilast 30 mg BID | 19.0 |
Placebo-Apremilast 20mg BID | 18.5 |
Placebo-Apremilast 30 mg BID | 25.9 |
PASI-90 response is the percentage of participants who achieved at least a 90% reduction (improvement) from baseline in PASI score at Week 40 of the extension study. The improvement in PASI score was used as a measure of efficacy. The PASI was a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). (NCT00773734)
Timeframe: Week 0 to Week 40
Intervention | percentage of participants (Number) |
---|---|
Apremilast 10mg BID | 8.5 |
Apremilast 20mg BID | 14.0 |
Apremilast 30 mg BID | 17.2 |
Placebo-Apremilast 20mg BID | 18.5 |
Placebo-Apremilast 30 mg BID | 22.2 |
PASI-90 response is the percentage of participants who achieved at least a 90% reduction (improvement) from baseline in PASI score at Week 52 of the extension study. The improvement in PASI score was used as a measure of efficacy. The PASI was a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). (NCT00773734)
Timeframe: Week 0 to Week 52
Intervention | percentage of participants (Number) |
---|---|
Apremilast 10mg BID | 4.3 |
Apremilast 20mg BID | 10.0 |
Apremilast 30 mg BID | 13.8 |
Placebo-Apremilast 20mg BID | 14.8 |
Placebo-Apremilast 30 mg BID | 11.1 |
The sPGA was a measure of psoriasis disease severity at the time of evaluation by the investigator. It does not compare assessments across visits or rely on investigator recall of prior disease severity. The sPGA was a 6-point scale ranging from 0 (clear, except for residual discoloration) to 5 (severe; majority of plaques have severe thickness, erythema, and scaling). The investigator examined all of the lesions on the participant and assigned a score ranging from 0 to 5 for thickness, erythema and degree of scaling . Scores for thickness, erythema and scaling are then summed and the mean of these 3 scores equaled the overall sPGA score. Fractional values for the sPGA were rounded to the next highest integer (eg, a score of 3.5 was rounded to 4, 3.4 was rounded to 3). A lower sPGA score was associated with less severe disease. (NCT00773734)
Timeframe: Week 0 to Week 32
Intervention | percentage of participants (Number) |
---|---|
Apremilast 10mg BID | 23.4 |
Apremilast 20mg BID | 26 |
Apremilast 30 mg BID | 44.8 |
Placebo-Apremilast 20mg BID | 33.3 |
Placebo-Apremilast 30 mg BID | 59.3 |
The sPGA was a measure of psoriasis disease severity at the time of evaluation by the investigator. It does not compare assessments across visits or rely on investigator recall of prior disease severity. The sPGA was a 6-point scale ranging from 0 (clear, except for residual discoloration) to 5 (severe; majority of plaques have severe thickness, erythema, and scaling). The investigator examined all of the lesions on the participant and assigned a score ranging from 0 to 5 for thickness, erythema and degree of scaling . Scores for thickness, erythema and scaling are then summed and the mean of these 3 scores equaled the overall sPGA score. Fractional values for the sPGA were rounded to the next highest integer (eg, a score of 3.5 was rounded to 4, 3.4 was rounded to 3). A lower sPGA score was associated with less disease. (NCT00773734)
Timeframe: Week 0 to Week 40
Intervention | percentage of participants (Number) |
---|---|
Apremilast 10mg BID | 23.4 |
Apremilast 20mg BID | 18.0 |
Apremilast 30 mg BID | 29.3 |
Placebo-Apremilast 20mg BID | 29.6 |
Placebo-Apremilast 30 mg BID | 37.0 |
The sPGA was a measure of psoriasis disease severity at the time of evaluation by the investigator. It does not compare assessments across visits or rely on investigator recall of prior disease severity. The sPGA was a 6-point scale ranging from 0 (clear, except for residual discoloration) to 5 (severe; majority of plaques have severe thickness, erythema, and scaling). The investigator examined all of the lesions on the participant and assigned a score ranging from 0 to 5 for thickness, erythema and degree of scaling . Scores for thickness, erythema and scaling are then summed and the mean of these 3 scores equaled the overall sPGA score. Fractional values for the sPGA were rounded to the next highest integer (eg, a score of 3.5 was rounded to 4, 3.4 was rounded to 3). A lower sPGA score was associated with less severe disease. (NCT00773734)
Timeframe: Week 0 to Week 52
Intervention | percentage of participants (Number) |
---|---|
Apremilast 10mg BID | 12.8 |
Apremilast 20mg BID | 10.0 |
Apremilast 30 mg BID | 22.4 |
Placebo-Apremilast 20mg BID | 33.3 |
Placebo-Apremilast 30 mg BID | 22.2 |
The DLQI was a validated, self-administered, 10-item questionnaire that measures the impact of skin disease on subjects' quality of life, based on recall over the past week. Domains include symptoms, feelings, daily activities, social, leisure, work or studying, personal relationships and treatment. Each question on the extent of the impact of skin disease was answered on a scale of 0 (not at all) to 3 (very much); the total DLQI score ranged from 0 to 30. A DLQI score greater than 10 is indicative of severe psoriasis. (NCT00773734)
Timeframe: Week 0 to Month 18
Intervention | units on a scale (Mean) |
---|---|
Apremilast 20mg BID | -6.5 |
The DLQI was a validated, self-administered, 10-item questionnaire that measures the impact of skin disease on subjects' quality of life, based on recall over the past week. Domains include symptoms, feelings, daily activities, social, leisure, work or studying, personal relationships and treatment. Each question on the extent of the impact of skin disease was answered on a scale of 0 (not at all) to 3 (very much); the total DLQI score ranged from 0 to 30. A DLQI score greater than 10 is indicative of severe psoriasis. (NCT00773734)
Timeframe: Week 0 to Month 24
Intervention | units on a scale (Mean) |
---|---|
Apremilast 10mg BID | -5.2 |
Placebo-Apremilast 20mg BID | -13.5 |
Apremilast 20mg BID | -5.9 |
Placebo-Apremilast 30 mg BID | -1.8 |
Apremilast 30 mg BID | -6.8 |
The DLQI was a validated, self-administered, 10-item questionnaire that measures the impact of skin disease on subjects' quality of life, based on recall over the past week. Domains include symptoms, feelings, daily activities, social, leisure, work or studying, personal relationships and treatment. Each question on the extent of the impact of skin disease was answered on a scale of 0 (not at all) to 3 (very much); the total DLQI score ranged from 0 to 30. A DLQI score greater than 10 is indicative of severe psoriasis. (NCT00773734)
Timeframe: Week 0 to Month 36
Intervention | units on a scale (Mean) |
---|---|
Apremilast 10mg BID | -11.7 |
Placebo-Apremilast 20mg BID | -3.0 |
Apremilast 20mg BID | -4.2 |
Placebo-Apremilast 30 mg BID | -2.0 |
Apremilast 30 mg BID | -6.0 |
The DLQI was a validated, self-administered, 10-item questionnaire that measures the impact of skin disease on subjects' quality of life, based on recall over the past week. Domains include symptoms, feelings, daily activities, social, leisure, work or studying, personal relationships and treatment. Each question on the extent of the impact of skin disease was answered on a scale of 0 (not at all) to 3 (very much); the total DLQI score ranged from 0 to 30. A DLQI score greater than 10 is indicative of severe psoriasis. (NCT00773734)
Timeframe: Week 0 to Month 48
Intervention | units on a scale (Mean) |
---|---|
Apremilast 10mg BID | -6.0 |
Placebo-Apremilast 20mg BID | -9.0 |
Apremilast 20mg BID | -3.5 |
Placebo-Apremilast 30 mg BID | -7.0 |
Apremilast 30 mg BID | -10.3 |
The SF-36 was a 36-item general health status instrument and consists of 8 scales: physical function (PF), role limitations-physical (RP), vitality (VT), general health perceptions (GH), bodily pain (BP), social function (SF), role limitations-emotional (RE), and mental health (MH). Scale scores range from 0 to 100, with higher scores indicating better health. Two overall summary scores were obtained - a Physical Component Summary score (PCS) and a Mental Component Summary score (MCS). Scores from the 8 scales, PCS and MCS were transformed to the norm-based scores using weights from U.S. general population, with 50 as the average and 10 as the standard deviation, higher scores indicating better health. For norm based scores, change from baseline were calculated for the 8 scales and the two summary scales, where change = visit value - baseline value. (NCT00773734)
Timeframe: Week 0 to Month 18
Intervention | units on a scale (Mean) |
---|---|
Apremilast 20mg BID | -2.8 |
The SF-36 was a 36-item general health status instrument and consists of 8 scales: physical function (PF), role limitations-physical (RP), vitality (VT), general health perceptions (GH), bodily pain (BP), social function (SF), role limitations-emotional (RE), and mental health (MH). Scale scores range from 0 to 100, with higher scores indicating better health. Two overall summary scores were obtained - a Physical Component Summary score (PCS) and a Mental Component Summary score (MCS). Scores from the 8 scales, PCS and MCS were transformed to the norm-based scores using weights from U.S. general population, with 50 as the average and 10 as the standard deviation, higher scores indicating better health. For norm based scores, change from baseline were calculated for the 8 scales and the two summary scales, where change = visit value - baseline value. (NCT00773734)
Timeframe: Week 0 to Month 24
Intervention | units on a scale (Mean) |
---|---|
Apremilast 10mg BID | 5.0 |
Placebo-Apremilast 20mg BID | 2.0 |
Apremilast 20mg BID | 5.2 |
Placebo-Apremilast 30 mg BID | 4.5 |
Apremilast 30 mg BID | 0.2 |
The SF-36 was a 36-item general health status instrument and consists of 8 scales: physical function (PF), role limitations-physical (RP), vitality (VT), general health perceptions (GH), bodily pain (BP), social function (SF), role limitations-emotional (RE), and mental health (MH). Scale scores range from 0 to 100, with higher scores indicating better health. Two overall summary scores were obtained - a Physical Component Summary score (PCS) and a Mental Component Summary score (MCS). Scores from the 8 scales, PCS and MCS were transformed to the norm-based scores using weights from U.S. general population, with 50 as the average and 10 as the standard deviation, higher scores indicating better health. For norm based scores, change from baseline were calculated for the 8 scales and the two summary scales, where change = visit value - baseline value. (NCT00773734)
Timeframe: Week 0 to Month 36
Intervention | units on a scale (Mean) |
---|---|
Apremilast 10mg BID | 6.0 |
Placebo-Apremilast 20mg BID | -2.7 |
Apremilast 20mg BID | 3.6 |
Placebo-Apremilast 30 mg BID | 2.1 |
Apremilast 30 mg BID | 2.4 |
The SF-36 was a 36-item general health status instrument and consists of 8 scales: physical function (PF), role limitations-physical (RP), vitality (VT), general health perceptions (GH), bodily pain (BP), social function (SF), role limitations-emotional (RE), and mental health (MH). Scale scores range from 0 to 100, with higher scores indicating better health. Two overall summary scores were obtained - a Physical Component Summary score (PCS) and a Mental Component Summary score (MCS). Scores from the 8 scales, PCS and MCS were transformed to the norm-based scores using weights from U.S. general population, with 50 as the average and 10 as the standard deviation, higher scores indicating better health. For norm based scores, change from baseline were calculated for the 8 scales and the two summary scales, where change = visit value - baseline value. (NCT00773734)
Timeframe: Week 0 to Month 48
Intervention | units on a scale (Mean) |
---|---|
Apremilast 10mg BID | -1.1 |
Placebo-Apremilast 20mg BID | 4.1 |
Apremilast 20mg BID | -1.0 |
Placebo-Apremilast 30 mg BID | 17.6 |
Apremilast 30 mg BID | 1.2 |
The SF-36 was a 36-item general health status instrument and consists of 8 scales: physical function (PF), role limitations-physical (RP), vitality (VT), general health perceptions (GH), bodily pain (BP), social function (SF), role limitations-emotional (RE), and mental health (MH). Scale scores range from 0 to 100, with higher scores indicating better health. Two overall summary scores were obtained - a Physical Component Summary score (PCS) and a Mental Component Summary score (MCS). Scores from the 8 scales, PCS and MCS were transformed to the norm-based scores using weights from U.S. general population, with 50 as the average and 10 as the standard deviation, higher scores indicating better health. For norm based scores, change from baseline were calculated for the 8 scales and the two summary scales, where change = visit value - baseline value. (NCT00773734)
Timeframe: Week 0 to Month 24
Intervention | units on a scale (Mean) |
---|---|
Apremilast 10mg BID | 4.1 |
Placebo-Apremilast 20mg BID | 3.7 |
Apremilast 20mg BID | 1.0 |
Placebo-Apremilast 30 mg BID | 2.4 |
Apremilast 30 mg BID | 5.0 |
The SF-36 was a 36-item general health status instrument and consists of 8 scales: physical function (PF), role limitations-physical (RP), vitality (VT), general health perceptions (GH), bodily pain (BP), social function (SF), role limitations-emotional (RE), and mental health (MH). Scale scores range from 0 to 100, with higher scores indicating better health. Two overall summary scores were obtained - a Physical Component Summary score (PCS) and a Mental Component Summary score (MCS). Scores from the 8 scales, PCS and MCS were transformed to the norm-based scores using weights from U.S. general population, with 50 as the average and 10 as the standard deviation, higher scores indicating better health. For norm based scores, change from baseline were calculated for the 8 scales and the two summary scales, where change = visit value - baseline value. (NCT00773734)
Timeframe: Week 0 to Month 36
Intervention | units on a scale (Mean) |
---|---|
Apremilast 10mg BID | 6.6 |
Placebo-Apremilast 20mg BID | 1.0 |
Apremilast 20mg BID | -0.1 |
Placebo-Apremilast 30 mg BID | 4.4 |
Apremilast 30 mg BID | 4.2 |
The SF-36 was a 36-item general health status instrument and consists of 8 scales: physical function (PF), role limitations-physical (RP), vitality (VT), general health perceptions (GH), bodily pain (BP), social function (SF), role limitations-emotional (RE), and mental health (MH). Scale scores range from 0 to 100, with higher scores indicating better health. Two overall summary scores were obtained - a Physical Component Summary score (PCS) and a Mental Component Summary score (MCS). Scores from the 8 scales, PCS and MCS were transformed to the norm-based scores using weights from U.S. general population, with 50 as the average and 10 as the standard deviation, higher scores indicating better health. For norm based scores, change from baseline were calculated for the 8 scales and the two summary scales, where change = visit value - baseline value. (NCT00773734)
Timeframe: Week 0 to Month 48
Intervention | units on a scale (Mean) |
---|---|
Apremilast 10mg BID | 1.4 |
Placebo-Apremilast 20mg BID | 2.0 |
Apremilast 20mg BID | -4.1 |
Placebo-Apremilast 30 mg BID | 10.2 |
Apremilast 30 mg BID | 9.4 |
The SF-36 was a 36-item general health status instrument and consists of 8 scales: physical function (PF), role limitations-physical (RP), vitality (VT), general health perceptions (GH), bodily pain (BP), social function (SF), role limitations-emotional (RE), and mental health (MH). Scale scores range from 0 to 100, with higher scores indicating better health. Two overall summary scores were obtained - a Physical Component Summary score (PCS) and a Mental Component Summary score (MCS). Scores from the 8 scales, PCS and MCS were transformed to the norm-based scores using weights from U.S. general population, with 50 as the average and 10 as the standard deviation, higher scores indicating better health. For norm based scores, change from baseline were calculated for the 8 scales and the two summary scales, where change = visit value - baseline value. (NCT00773734)
Timeframe: Week 0 to Month 18
Intervention | units on a scale (Mean) |
---|---|
Apremilast 20mg BID | 10.2 |
"The overall BSA affected by psoriasis was estimated by comparison of the size of the affected area to the palm area of the participant's hand (entire palmar surface or handprint), which equates to approximately 1% of total BSA." (NCT00773734)
Timeframe: Week 0 to Month 18
Intervention | percent change (Median) |
---|---|
Apremilast 10mg BID | -78.6 |
Placebo-Apremilast 20 mg BID | -73.9 |
Apremilast 20mg BID | -73.3 |
Placebo-Apremilast 30 mg BID | -49.2 |
Apremilast 30 mg BID | -86.4 |
"The overall BSA affected by psoriasis was estimated by comparison of the size of the affected area to the palm area of the participant's hand (entire palmar surface or handprint), which equates to approximately 1% of total BSA." (NCT00773734)
Timeframe: Week 0 to Month 24
Intervention | percent change (Median) |
---|---|
Apremilast 10mg BID | -60.5 |
Placebo-Apremilast 20 mg BID | -66.2 |
Apremilast 20mg BID | -75.0 |
Apremilast 30 mg BID | -41.5 |
Placebo-Apremilast 30 mg BID | -77.4 |
"The overall BSA affected by psoriasis was estimated by comparison of the size of the affected area to the palm area of the participant's hand (entire palmar surface or handprint), which equates to approximately 1% of total BSA." (NCT00773734)
Timeframe: Week 0 to Month 36
Intervention | percent change (Median) |
---|---|
Apremilast 10mg BID | -85.7 |
Placebo-Apremilast 20 mg BID | -63.4 |
Apremilast 20mg BID | -60.9 |
Placebo-Apremilast 30 mg BID | -52.2 |
Apremilast 30 mg BID | -81.0 |
"The overall BSA affected by psoriasis was estimated by comparison of the size of the affected area to the palm area of the participant's hand (entire palmar surface or handprint), which equates to approximately 1% of total BSA." (NCT00773734)
Timeframe: Week 0 to Month 48
Intervention | percent change (Median) |
---|---|
Apremilast 10mg BID | -75.0 |
Placebo-Apremilast 20 mg BID | -50.6 |
Apremilast 20mg BID | -73.5 |
Placebo-Apremilast 30 mg BID | -75.0 |
Apremilast 30 mg BID | -91.9 |
The PASI is a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness, and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling were scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions was scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). The total qualitative score (sum of erythema, thickness, and scaling scores) was multiplied by the degree of involvement for each anatomic region and then multiplied by a constant. The values for each anatomic region were summed to yield the PASI score (NCT00773734)
Timeframe: Week 0 to Month 18
Intervention | percent change (Mean) |
---|---|
Apremilast 10mg BID | -71.8 |
PBO-Apremilast 20mg BID | -60.5 |
Apremilast 20mg BID | -65.3 |
PBO-Apremilast 30 mg BID | -50.0 |
Apremilast 30 mg BID | -77.3 |
The PASI is a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness, and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling were scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions was scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). The total qualitative score (sum of erythema, thickness, and scaling scores) was multiplied by the degree of involvement for each anatomic region and then multiplied by a constant. The values for each anatomic region were summed to yield the PASI score (NCT00773734)
Timeframe: Week 0 to Month 24
Intervention | percent change (Mean) |
---|---|
Apremilast 10mg BID | -57.8 |
PBO-Apremilast 20mg BID | -64.5 |
Apremilast 20mg BID | -65.9 |
PBO-Apremilast 30 mg BID | -46.0 |
Apremilast 30 mg BID | -78.4 |
The PASI is a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness, and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling were scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions was scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). The total qualitative score (sum of erythema, thickness, and scaling scores) was multiplied by the degree of involvement for each anatomic region and then multiplied by a constant. The values for each anatomic region were summed to yield the PASI score (NCT00773734)
Timeframe: Week 0 to Month 36
Intervention | percent change (Mean) |
---|---|
Apremilast 10mg BID | -87.7 |
PBO-Apremilast 20mg BID | -69.0 |
Apremilast 20mg BID | -48.8 |
PBO-Apremilast 30 mg BID | -48.0 |
Apremilast 30 mg BID | -80.0 |
The PASI is a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness, and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling were scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions was scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). The total qualitative score (sum of erythema, thickness, and scaling scores) was multiplied by the degree of involvement for each anatomic region and then multiplied by a constant. The values for each anatomic region were summed to yield the PASI score (NCT00773734)
Timeframe: Week 0 to Month 48
Intervention | percent change (Mean) |
---|---|
Apremilast 10mg BID | -82.5 |
PBO-Apremilast 20mg BID | -52.0 |
Apremilast 20mg BID | -54.3 |
PBO-Apremilast 30 mg BID | -80.0 |
Apremilast 30 mg BID | -85.0 |
"The overall BSA affected by psoriasis was estimated by comparison of the size of the affected area to the palm area of the participant's hand (entire palmar surface or handprint), which equates to approximately 1% of total BSA." (NCT00773734)
Timeframe: Week 0 to Month 18
Intervention | percent change (Mean) |
---|---|
Apremilast 10mg BID | -71.1 |
Placebo-Apremilast 20 mg BID | -73.9 |
Apremilast 20mg BID | -74.2 |
Placebo-Apremilast 30 mg BID | -44.2 |
Apremilast 30 mg BID | -76.7 |
"The overall BSA affected by psoriasis was estimated by comparison of the size of the affected area to the palm area of the participant's hand (entire palmar surface or handprint), which equates to approximately 1% of total BSA." (NCT00773734)
Timeframe: Week 0 to Month 24
Intervention | percent change (Mean) |
---|---|
Apremilast 10mg BID | -64.7 |
Placebo-Apremilast 20 mg BID | -66.2 |
Apremilast 20mg BID | -74.5 |
Placebo-Apremilast 30 mg BID | -24.7 |
Apremilast 30 mg BID | -74.5 |
"The overall BSA affected by psoriasis was estimated by comparison of the size of the affected area to the palm area of the participant's hand (entire palmar surface or handprint), which equates to approximately 1% of total BSA." (NCT00773734)
Timeframe: Week 0 to Month 36
Intervention | percent change (Mean) |
---|---|
Apremilast 10mg BID | -86.1 |
Placebo-Apremilast 20 mg BID | -63.4 |
Apremilast 20mg BID | -58.4 |
Placebo-Apremilast 30 mg BID | -39.1 |
Apremilast 30 mg BID | -78.5 |
"The overall BSA affected by psoriasis was estimated by comparison of the size of the affected area to the palm area of the participant's hand (entire palmar surface or handprint), which equates to approximately 1% of total BSA." (NCT00773734)
Timeframe: Week 0 to Month 48
Intervention | percent change (Mean) |
---|---|
Apremilast 10mg BID | -75.0 |
Placebo-Apremilast 20 mg BID | -50.6 |
Apremilast 20mg BID | -72.4 |
Placebo-Apremilast 30 mg BID | -75.0 |
Apremilast 30 mg BID | -86.1 |
PASI-50 response is the percentage of participants who achieved at least a 50% reduction (improvement) from baseline in PASI score. The improvement in PASI score was used as a measure of efficacy. The PASI was a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). (NCT00773734)
Timeframe: Week 0 to Month 18
Intervention | percentage of participants (Number) |
---|---|
Apremilast 10mg BID | 100.0 |
Placebo-Apremilast 20mg BID | 50.0 |
Apremilast 20mg BID | 70.0 |
Placebo-Apremilast 30 mg BID | 50.0 |
Apremilast 30 mg BID | 100 |
PASI-50 response is the percentage of participants who achieved at least a 50% reduction (improvement) from baseline in PASI score. The improvement in PASI score was used as a measure of efficacy. The PASI was a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). (NCT00773734)
Timeframe: Week 0 to Month 24
Intervention | percentage of participants (Number) |
---|---|
Apremilast 10mg BID | 60.0 |
Placebo-Apremilast 20mg BID | 50.0 |
Apremilast 20mg BID | 50.0 |
Placebo-Apremilast 30 mg BID | 25.0 |
Apremilast 30 mg BID | 90.0 |
PASI-50 response is the percentage of participants who achieved at least a 50% reduction (improvement) from baseline in PASI score. The improvement in PASI score was used as a measure of efficacy. The PASI was a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). (NCT00773734)
Timeframe: Week 0 to Month 36
Intervention | percentage of participants (Number) |
---|---|
Apremilast 10mg BID | 60.0 |
Placebo-Apremilast 20mg BID | 50.0 |
Apremilast 20mg BID | 30.0 |
Placebo-Apremilast 30 mg BID | 50.0 |
Apremilast 30 mg BID | 60.0 |
PASI-50 response is the percentage of participants who achieved at least a 50% reduction (improvement) from baseline in PASI score. The improvement in PASI score was used as a measure of efficacy. The PASI was a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). (NCT00773734)
Timeframe: Week 0 to Month 48
Intervention | percentage of participants (Number) |
---|---|
Apremilast 10mg BID | 40.0 |
Placebo-Apremilast 20mg BID | 25.0 |
Apremilast 20mg BID | 20.0 |
Placebo-Apremilast 30 mg BID | 25.0 |
Apremilast 30 mg BID | 40.0 |
PASI-75 response is the percentage of participants who achieved at least a 75% reduction (improvement) from baseline in PASI score. The improvement in PASI score was used as a measure of efficacy. The PASI was a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). (NCT00773734)
Timeframe: Week 0 to Month 18
Intervention | percentage of participants (Number) |
---|---|
Apremilast 10mg BID | 60.0 |
Placebo-Apremilast 20mg BID | 0.0 |
Apremilast 20mg BID | 40.0 |
Placebo-Apremilast 30 mg BID | 0.0 |
Apremilast 30 mg BID | 50.0 |
PASI-75 response is the percentage of participants who achieved at least a 75% reduction (improvement) from baseline in PASI. The improvement in PASI score was used as a measure of efficacy. The PASI was a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). (NCT00773734)
Timeframe: Week 0 to Month 24
Intervention | percentage of participants (Number) |
---|---|
Apremilast 10mg BID | 20.0 |
Placebo-Apremilast 20mg BID | 0.0 |
Apremilast 20mg BID | 30.0 |
Placebo-Apremilast 30 mg BID | 25.0 |
Apremilast 30 mg BID | 50.0 |
PASI-75 response is the percentage of participants who achieved at least a 75% reduction (improvement) from baseline in PASI score. The improvement in PASI score was used as a measure of efficacy. The PASI was a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). (NCT00773734)
Timeframe: Week 0 to Month 36
Intervention | percentage of participants (Number) |
---|---|
Apremilast 10mg BID | 60.0 |
Placebo-Apremilast 20mg BID | 25.0 |
Apremilast 20mg BID | 10.0 |
Placebo-Apremilast 30 mg BID | 0.0 |
Apremilast 30 mg BID | 30.0 |
PASI-75 response is the percentage of participants who achieved at least a 75% reduction (improvement) from baseline in PASI score. The improvement in PASI score was used as a measure of efficacy. The PASI was a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). (NCT00773734)
Timeframe: Week 0 to Month 48
Intervention | percentage of participants (Number) |
---|---|
Apremilast 10mg BID | 40.0 |
Placebo-Apremilast 20mg BID | 0.0 |
Apremilast 20mg BID | 0 |
Placebo-Apremilast 30 mg BID | 25.0 |
Apremilast 30 mg BID | 30.0 |
PASI-90 response is the percentage of participants who achieved at least a 90% reduction (improvement) from baseline in PASI score at Week 76 of the long-term extension study. The improvement in PASI score was used as a measure of efficacy. The PASI was a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). (NCT00773734)
Timeframe: Week 0 to Month 18
Intervention | percentage of participants (Number) |
---|---|
Apremilast 10mg BID | 0.0 |
Placebo-Apremilast 20mg BID | 0.0 |
Apremilast 20mg BID | 10.0 |
Placebo-Apremilast 30 mg BID | 0.0 |
Apremilast 30 mg BID | 30.0 |
PASI-90 response is the percentage of participants who achieved at least a 90% reduction (improvement) from baseline in PASI score at Week 100 of the extension study. The improvement in PASI score was used as a measure of efficacy. The PASI was a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). (NCT00773734)
Timeframe: Week 0 to Month 24
Intervention | percentage of participants (Number) |
---|---|
Apremilast 10mg BID | 0.0 |
Placebo-Apremilast 20mg BID | 0 |
Apremilast 20mg BID | 10.0 |
Placebo-Apremilast 30 mg BID | 0.0 |
Apremilast 30 mg BID | 30.0 |
PASI-90 response is the percentage of participants who achieved at least a 90% reduction (improvement) from baseline in PASI score at Week 148 of the extension study. The improvement in PASI score was used as a measure of efficacy. The PASI was a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). (NCT00773734)
Timeframe: Week 0 to Month 36
Intervention | percentage of participants (Number) |
---|---|
Apremilast 10mg BID | 20.0 |
Placebo-Apremilast 20mg BID | 0.0 |
Apremilast 20mg BID | 10.0 |
Placebo-Apremilast 30 mg BID | 0.0 |
Apremilast 30 mg BID | 20.0 |
PASI-90 response is the percentage of participants who achieved at least a 90% reduction (improvement) from baseline in PASI score at Week 196 of the extension study. The improvement in PASI score was used as a measure of efficacy. The PASI was a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). (NCT00773734)
Timeframe: Week 0 to Month 48
Intervention | percentage of participants (Number) |
---|---|
Apremilast 10mg BID | 0.0 |
Placebo-Apremilast 20mg BID | 0.0 |
Apremilast 20mg BID | 0.0 |
Placebo-Apremilast 30 mg BID | 0.0 |
Apremilast 30 mg BID | 20.0 |
The sPGA was a measure of psoriasis disease severity at the time of evaluation by the investigator. It does not compare assessments across visits or rely on investigator recall of prior disease severity. The sPGA was a 6-point scale ranging from 0 (clear, except for residual discoloration) to 5 (severe; majority of plaques have severe thickness, erythema, and scaling). The investigator examined all of the lesions on the participant and assigned a score ranging from 0 to 5 for thickness, erythema and degree of scaling . Scores for thickness, erythema and scaling are then summed and the mean of these 3 scores equaled the overall sPGA score. Fractional values for the sPGA were rounded to the next highest integer (eg, a score of 3.5 was rounded to 4, 3.4 was rounded to 3). A lower sPGA score was associated with less severe disease (NCT00773734)
Timeframe: Week 0 to Month 18
Intervention | percentage of participants (Number) |
---|---|
Apremilast 10mg BID | 60.0 |
Placebo-Apremilast 20 mg BID | 0.0 |
Apremilast 20mg BID | 20.0 |
Placebo-Apremilast 30 mg BID | 25.0 |
Apremilast 30 mg BID | 60.0 |
The sPGA was a measure of psoriasis disease severity at the time of evaluation by the investigator. It does not compare assessments across visits or rely on investigator recall of prior disease severity. The sPGA was a 6-point scale ranging from 0 (clear, except for residual discoloration) to 5 (severe; majority of plaques have severe thickness, erythema, and scaling). The investigator examined all of the lesions on the participant and assigned a score ranging from 0 to 5 for thickness, erythema and degree of scaling . Scores for thickness, erythema and scaling are then summed and the mean of these 3 scores equaled the overall sPGA score. Fractional values for the sPGA were rounded to the next highest integer (eg, a score of 3.5 was rounded to 4, 3.4 was rounded to 3). A lower sPGA score was associated with less severe disease (NCT00773734)
Timeframe: Week 0 to Month 24
Intervention | percentage of participants (Number) |
---|---|
Apremilast 10mg BID | 20.0 |
Placebo-Apremilast 20 mg BID | 0.00 |
Apremilast 20mg BID | 10.0 |
Placebo-Apremilast 30 mg BID | 25.0 |
Apremilast 30 mg BID | 40.0 |
The sPGA was a measure of psoriasis disease severity at the time of evaluation by the investigator. It does not compare assessments across visits or rely on investigator recall of prior disease severity. The sPGA was a 6-point scale ranging from 0 (clear, except for residual discoloration) to 5 (severe; majority of plaques have severe thickness, erythema, and scaling). The investigator examined all of the lesions on the participant and assigned a score ranging from 0 to 5 for thickness, erythema and degree of scaling . Scores for thickness, erythema and scaling are then summed and the mean of these 3 scores equaled the overall sPGA score. Fractional values for the sPGA were rounded to the next highest integer (eg, a score of 3.5 was rounded to 4, 3.4 was rounded to 3). A lower sPGA score was associated with less severe disease (NCT00773734)
Timeframe: Week 0 and month 36
Intervention | percentage of participants (Number) |
---|---|
Apremilast 10mg BID | 60.0 |
Placebo-Apremilast 20 mg BID | 0.0 |
Apremilast 20mg BID | 0 |
Placebo-Apremilast 30 mg BID | 25.0 |
Apremilast 30 mg BID | 30.0 |
The sPGA was a measure of psoriasis disease severity at the time of evaluation by the investigator. It does not compare assessments across visits or rely on investigator recall of prior disease severity. The sPGA was a 6-point scale ranging from 0 (clear, except for residual discoloration) to 5 (severe; majority of plaques have severe thickness, erythema, and scaling). The investigator examined all of the lesions on the participant and assigned a score ranging from 0 to 5 for thickness, erythema and degree of scaling . Scores for thickness, erythema and scaling are then summed and the mean of these 3 scores equaled the overall sPGA score. Fractional values for the sPGA were rounded to the next highest integer (eg, a score of 3.5 was rounded to 4, 3.4 was rounded to 3). A lower sPGA score was associated with less severe disease (NCT00773734)
Timeframe: Week 0 to Month 48
Intervention | percentage of participants (Number) |
---|---|
Apremilast 10mg BID | 20.0 |
Placebo-Apremilast 20 mg BID | 0.0 |
Apremilast 20mg BID | 0.0 |
Placebo-Apremilast 30 mg BID | 25.0 |
Apremilast 30 mg BID | 30.0 |
Time to loss of response was modified to be 50% loss in the PASI response observed at the end of treatment for participants who achieved at least a PASI-50 at the end of treatment. This definition was changed since participants may have already lost their maximal PASI response prior to enrollment into the Observation Follow-up Phase. Included all participants that enrolled into the observational follow-up phase after the treatment phase. (NCT00773734)
Timeframe: Up to 4 weeks after the last dose
Intervention | weeks (Median) |
---|---|
Apremilast 10mg BID | NA |
Apremilast 20mg BID | NA |
Apremilast 30 mg BID | NA |
Placebo-Apremilast 20mg BID | NA |
Placebo-Apremilast 30 mg BID | 5.3 |
An AE was any noxious, unintended, or untoward medical occurrence, that may appear or worsen in a participant during the course of study. It may be a new intercurrent illness, a worsening concomitant illness, an injury, or any concomitant impairment of the participant's health, including laboratory test values regardless of etiology. Any worsening (ie, any clinically significant adverse change in the frequency or intensity of a preexisting condition) was considered an AE. A serious AE (SAE) is any untoward adverse event that is fatal, life-threatening, results in persistent or significant disability or incapacity, requires or prolongs existing in-patient hospitalization, is a congenital anomaly/birth defect, or is a condition that may jeopardize the patient or may require intervention to prevent one of the outcomes listed above. An AE is a treatment emergent AE if the AE start date is on or after the date of the first dose of study drug and no later than 28 days after the last dose. (NCT00773734)
Timeframe: Week 0 to 6 years of study treatment; maximum duration of exposure was 314.6 weeks
Intervention | participants (Number) | |||||||
---|---|---|---|---|---|---|---|---|
Any treatment emergent AE | Any drug-related TEAE | Any severe TEAE | Any serious TEAE | Any serious drug-related | ≥ 1 TEAE leading to drug interruption | ≥ 1 TEAE leading to drug withdrawal | ≥ 1 TEAE leading to death | |
Apremilast 10mg BID | 67 | 23 | 4 | 2 | 0 | 3 | 5 | 0 |
Apremilast 20mg BID | 97 | 32 | 10 | 9 | 1 | 11 | 11 | 0 |
Apremilast 30 mg BID | 111 | 46 | 14 | 6 | 0 | 10 | 16 | 0 |
An AE was any noxious, unintended, or untoward medical occurrence, that may appear or worsen in a participant during the course of study. It may be a new intercurrent illness, a worsening concomitant illness, an injury, or any concomitant impairment of the participant's health, including laboratory test values regardless of etiology. Any worsening (ie, any clinically significant adverse change in the frequency or intensity of a preexisting condition) was considered an AE. A serious AE (SAE) is any untoward adverse event that is fatal, life-threatening, results in persistent or significant disability or incapacity, requires or prolongs existing in-patient hospitalization, is a congenital anomaly/birth defect, or is a condition that may jeopardize the patient or may require intervention to prevent one of the outcomes listed above. An AE is a treatment emergent AE if the AE start date is on or after the date of the first dose of study drug and no later than 28 days after the last dose. (NCT00773734)
Timeframe: Week 0-88; up to data cut off of 21 July 2011
Intervention | participants (Number) | |||||||
---|---|---|---|---|---|---|---|---|
Any treatment emergent AE | Any drug-related TEAE | Any severe TEAE | Any serious TEAE | Any serious drug-related | ≥ 1 TEAE leading to drug interruption | ≥ 1 TEAE leading to drug withdrawal | ≥ 1 TEAE leading to death | |
Apremilast 10mg BID | 67 | 23 | 3 | 1 | 0 | 3 | 5 | 0 |
Apremilast 20mg BID | 97 | 31 | 9 | 8 | 1 | 11 | 11 | 0 |
Apremilast 30 mg BID | 110 | 45 | 13 | 6 | 0 | 9 | 15 | 0 |
An AE was any noxious, unintended, or untoward medical occurrence, that may appear or worsen in a participant during the course of study. It may be a new intercurrent illness, a worsening concomitant illness, an injury, or any concomitant impairment of the participant's health, including laboratory test values regardless of etiology. Any worsening (ie, any clinically significant adverse change in the frequency or intensity of a preexisting condition) was considered an AE. A serious AE (SAE) is any untoward adverse event that is fatal, life-threatening, results in persistent or significant disability or incapacity, requires or prolongs existing in-patient hospitalization, is a congenital anomaly/birth defect, or is a condition that may jeopardize the patient or may require intervention to prevent one of the outcomes listed above. An AE is a treatment emergent AE if the AE start date is on or after the date of the first dose of study drug and no later than 28 days after the last dose. (NCT00773734)
Timeframe: Week 0 to Week 16; up to data cut off of 21 July 2011
Intervention | participants (Number) | |||||||
---|---|---|---|---|---|---|---|---|
Any treatment emergent AE | Any drug-related TEAE | Any severe TEAE | Any serious TEAE | Any serious drug-related | ≥ 1 TEAE leading to drug interruption | ≥ 1 TEAE leading to drug withdrawal | ≥ 1 TEAE leading to death | |
Apremilast 10mg BID | 59 | 20 | 1 | 0 | 0 | 3 | 2 | 0 |
Apremilast 20mg BID | 67 | 23 | 5 | 3 | 0 | 3 | 8 | 0 |
Apremilast 30 mg BID | 72 | 32 | 5 | 4 | 0 | 6 | 12 | 0 |
Placebo | 57 | 11 | 3 | 2 | 0 | 4 | 5 | 1 |
"DLQI is questionnaire for use in a dermatology clinical setting to assess limitations related to the impact of skin disease. The instrument contains ten items dealing with the participant's skin. With the exception of Item Number 7, the participant responds on a four-point scale, ranging from Very Much (score 3) to Not at All or Not relevant (score 0). Item Number 7 is a multi-part item, the first part of which ascertains whether the participant's skin prevented them from working or studying (Yes or No, scores 3 or 0 respectively), and if No, then the subject is asked how much of a problem the skin has been at work or study over the past week, with response alternatives being A lot, A little, or Not at all (scores 2, 1, or 0 respectively). The DLQI total score was derived by summing all item scores, and has a possible range of 0 to 30, with 30 corresponding to the worst quality of life, and 0 corresponding to the best." (NCT03123471)
Timeframe: Baseline to Week 16
Intervention | Units on a Scale (Least Squares Mean) |
---|---|
Placebo/Apremilast | -3.8 |
Apremilast | -6.7 |
"The scalp itch NRS is a 11-point scale to assess scalp itch. The scale ranges from 0-10, where 0 represents no itch, and 10 represents the worst imaginable itch." (NCT03123471)
Timeframe: Baseline to Week 16
Intervention | Percentage of Participants (Number) |
---|---|
Placebo/Apremilast | 21.1 |
Apremilast | 47.1 |
"The Whole Body Itch NRS scale is an 11-point scale to assess whole body itch. The scale ranges from 0-10, where 0 represents no itch, and 10 represents the worst imaginable itch, and a 4-point change from baseline was shown to be optimal for demonstrating a level of clinically meaningful improvement in itch severity. NRS response was defined as a ≥ 4-point reduction (improvement) from baseline." (NCT03123471)
Timeframe: Baseline to Week 16
Intervention | Percentage of Participants (Number) |
---|---|
Placebo/Apremilast | 22.5 |
Apremilast | 45.5 |
The ScPGA is a measurement of overall scalp involvement by the investigator at the time of evaluation. The ScPGA is a 5-point scale ranging from 0 (clear) to 4 (severe), incorporating an assessment of the severity of the 3 primary signs of the disease: erythema, scaling, and plaque elevation. When making the assessment of overall scalp severity, the investigator factored in areas that had already been cleared (ie, had scores of 0), not limited to the evaluation of remaining lesions for severity; consequently, the severity of each sign was averaged across all areas of involvement, including cleared lesions. (NCT03123471)
Timeframe: Baseline to Week 16
Intervention | Percentage of Participants (Number) |
---|---|
Placebo/Apremilast | 13.7 |
Apremilast | 43.3 |
A TEAE is an AE with a start date on or after the date of the first dose of study drug and no later than 28 days after the last dose of study drug. A serious AE (SAE) is any untoward AE that is fatal, life-threatening, results in persistent or significant disability or incapacity, requires or prolongs existing in-patient hospitalization, is a congenital anomaly/birth defect, or is a condition that may jeopardize or may require intervention to prevent one of the outcomes above. The severity of AEs was assessed based on the following scale: Mild = asymptomatic or mild symptoms, clinical or diagnostic observations only; Moderate = symptoms cause moderate discomfort; Severe = could be non-serious or serious) = symptoms causing severe pain discomfort. (NCT03123471)
Timeframe: Week 0 to Week 16; mean duration of exposure was 14.5 weeks and 14.6 weeks for participants randomized to placebo and apremilast respectively.
Intervention | Participants (Count of Participants) | |||||
---|---|---|---|---|---|---|
Any TEAE | Any Drug-related TEAE | Any Severe TEAE | Any Serious TEAE | Any TEAE Leading to Drug Interruption | Any TEAE Leading to Drug Withdrawal | |
Apremilast | 135 | 99 | 5 | 2 | 9 | 11 |
Placebo/Apremilast | 52 | 22 | 2 | 1 | 4 | 3 |
The apremilast-exposure period started on the date of the first dose of apremilast (Week 0 for participants originally randomized to apremilast or Week 16 for participants originally randomized to placebo) to the last dose of apremilast. A TEAE is an AE with a start date on or after the date of the first dose of study drug and no later than 28 days after the last dose of study drug. A serious AE (SAE) is any untoward AE that is fatal, life-threatening, results in persistent or significant disability or incapacity, requires or prolongs existing in-patient hospitalization, is a congenital anomaly/birth defect, or is a condition that may jeopardize or may require intervention to prevent one of the outcomes above. The severity of AEs was assessed based on the following scale: Mild = asymptomatic or mild symptoms, clinical or diagnostic observations only; Moderate = symptoms cause moderate discomfort; Severe = could be non-serious or serious) = symptoms causing severe pain discomfort. (NCT03123471)
Timeframe: Week 0 to 32;
Intervention | Participants (Count of Participants) | |||||||
---|---|---|---|---|---|---|---|---|
Any TEAE | Any Drug-related TEAE | Any Severe TEAE | Any Serious TEAE | Any Serious TEAE Drug Related TEAE | Any TEAE Leading to Drug Interruption | Any TEAE Leading to Drug Withdrawal | Deaths | |
Apremilast | 144 | 103 | 8 | 6 | 3 | 13 | 15 | 0 |
Placebo/Apremilast | 35 | 17 | 2 | 1 | 0 | 2 | 1 | 0 |
A TEAE is an AE with a start date on or after the date of the first dose of study drug and no later than 28 days after the last dose of study drug. A serious AE (SAE) is any untoward AE that is fatal, life-threatening, results in persistent or significant disability or incapacity, requires or prolongs existing in-patient hospitalization, is a congenital anomaly/birth defect, or is a condition that may jeopardize or may require intervention to prevent one of the outcomes above. The severity of AEs was assessed based on the following scale: Mild = asymptomatic or mild symptoms, clinical or diagnostic observations only; Moderate = symptoms cause moderate discomfort; Severe = could be non-serious or serious) = symptoms causing severe pain discomfort. (NCT03123471)
Timeframe: Weeks 16 to Week 32; the mean treatment duration was 14.6 weeks and 15.3 weeks in the APR 30/APR 30 BID and placebo/APR 30 BID arms, respectively
Intervention | Participants (Count of Participants) | ||||||
---|---|---|---|---|---|---|---|
Any TEAE | Any Drug-related TEAE | Any Severe TEAE | Any Serious TEAE | Any TEAE Leading to Drug Interruption | Any TEAE Leading to Drug Withdrawal | Deaths | |
Apremilast | 66 | 17 | 4 | 5 | 4 | 4 | 0 |
Placebo/Apremilast | 35 | 17 | 2 | 1 | 2 | 1 | 0 |
"The scalp itch NRS is a 11-point scale to assess scalp itch. The scale ranges from 0-10, where 0 represents no itch, and 10 represents the worst imaginable itch." (NCT03123471)
Timeframe: Baseline to Weeks 2, 4, 8 and 12
Intervention | Percentage of Participants (Number) | |||
---|---|---|---|---|
Week 2 | Week 4 | Week 8 | Week 12 | |
Apremilast | 26.1 | 37.8 | 45.6 | 46.5 |
Placebo/Apremilast | 11.5 | 16.5 | 23.7 | 19.6 |
"The Whole Body Itch NRS scale is a 11-point scale to assess whole body itch. The scale ranges from 0-10, where 0 represents no itch, and 10 represents the worst imaginable itch, and a 4-point change from baseline was shown to be optimal for demonstrating a level of clinically meaningful improvement in itch severity." (NCT03123471)
Timeframe: Baseline to Weeks 2, 4, 6, 8 and 12
Intervention | Percentage of Participants (Number) | |||
---|---|---|---|---|
Week 2 | Week 4 | Week 8 | Week 12 | |
Apremilast | 20.5 | 32.3 | 39.8 | 47.0 |
Placebo/Apremilast | 3.5 | 10.1 | 19.7 | 26.3 |
Live lice eradication was assessed by visual checks of hair and scalp on Days 1, 2 and 8 and by visual checks and counting both live and dead lice from rinse water on Day 15. Eradication was defined as cessation of motility (antennae and leg movement) in all lice. (NCT00857948)
Timeframe: Day 1 through Day 15 post-application
Intervention | Percent of participants (Number) |
---|---|
0.15% Ivermectin | 56 |
0.25% Ivermectin | 50 |
0.50% Ivermectin | 74 |
Placebo | 9 |
The severity of lice infestation was determined by visual checks of hair and scalp. Severity was rated as None: no live lice; Mild: 1 to 5 live lice; Moderate: 6 to 10 live lice; Severe: 11 to 20 live lice; or Very severe > 20 live lice. (NCT00857948)
Timeframe: Day 1 through Day 15 post-application
Intervention | Percent of participants (Number) | ||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Day 1: 2 Hours Post Dose: None | Day 1: 2 Hours Post Dose: Mild | Day 1: 2 Hours Post Dose: Moderate | Day 1: 6 Hours Post Dose: None | Day 1: 6 Hours Post Dose: Mild | Day 1: 6 Hours Post Dose: Moderate | Day 2: None | Day 2: Mild | Day 2: Moderate | Day 8: Treatment Failure Day 2 | Day 8: None | Day 8: Mild | Day 8: Moderate | Day 8: Severe | Day 15: Treatment Failure Day 8 | Day 15: None | Day 15: Mild | |
0.15% Ivermectin | 33 | 50 | 17 | 50 | 39 | 11 | 83 | 17 | 0 | 17 | 72 | 11 | 0 | 0 | 33 | 56 | 11 |
0.25% Ivermectin | 44 | 56 | 0 | 67 | 33 | 0 | 94 | 6 | 0 | 6 | 72 | 6 | 6 | 11 | 28 | 56 | 17 |
0.50% Ivermectin | 32 | 63 | 5 | 58 | 37 | 5 | 95 | 5 | 0 | 5 | 84 | 5 | 0 | 5 | 16 | 74 | 11 |
Placebo | 22 | 65 | 13 | 30 | 61 | 9 | 17 | 78 | 4 | 83 | 9 | 9 | 0 | 0 | 91 | 9 | 0 |
(NCT00857948)
Timeframe: Day 1 up to Day 28 post-application
Intervention | Participants (Number) | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Conjunctivitis | Severe Conjunctivitis | Eye Pruritus | Severe Eye Pruritus | Erythema | Severe Erythema | Folliculitis | Severe Folliculitis | Pruritus | Severe Pruritus | Skin Irritation | Severe Skin Irritation | |
0.15% Ivermectin | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 5 | 0 | 0 | 0 |
0.25% Ivermectin | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 |
0.50% Ivermectin | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 3 | 0 | 0 | 0 |
Placebo | 0 | 0 | 0 | 0 | 3 | 0 | 1 | 0 | 1 | 0 | 1 | 0 |
Live lice eradication was assessed on Days 1, 2, and 8 by visual checks of hair and scalp. Eradication was defined as cessation of motility (antennae and leg movement) in all lice. (NCT00857948)
Timeframe: Day 1 through Day 8 post-application
Intervention | Percent of participants (Number) | |||
---|---|---|---|---|
Day 1: 2 hours post-application | Day 1: 6 hours post-application | Day 2 | Day 8 | |
0.15% Ivermectin | 33 | 50 | 83 | 67 |
0.25% Ivermectin | 44 | 67 | 94 | 72 |
0.50% Ivermectin | 32 | 58 | 95 | 84 |
Placebo | 22 | 30 | 17 | 9 |
9 reviews available for salicylic acid and Pruritus
Article | Year |
---|---|
The management of chronic pruritus in the elderly.
Topics: Administration, Oral; Administration, Topical; Aged; Antipruritics; Cannabinoids; Capsaicin; Central | 2010 |
Scalp dysesthesia: a neuropathic phenomenon.
Topics: Aged; COVID-19; Female; Humans; Paresthesia; Pruritus; Scalp; Skin Diseases | 2022 |
[Tinea capitis in children is an overlooked disease].
Topics: Alopecia; Antifungal Agents; Child; Humans; Pain; Pruritus; Scalp; Tinea Capitis | 2020 |
Multiple Warty Dyskeratomas With Severe Pruritus: A Case Report and Literature Review.
Topics: Female; Head and Neck Neoplasms; Humans; Middle Aged; Pruritus; Scalp; Skin Neoplasms | 2018 |
Scalp Pruritus: Review of the Pathogenesis, Diagnosis, and Management.
Topics: Animals; Humans; Pruritus; Quality of Life; Scalp; Skin | 2019 |
Neurocutaneous disease: Neurocutaneous dysesthesias.
Topics: Facial Dermatoses; Femoral Neuropathy; Humans; Nerve Compression Syndromes; Paresthesia; Pruritus; S | 2016 |
The itchy scalp--scratching for an explanation.
Topics: Animals; Humans; Pruritus; Scalp; Sebum | 2011 |
[Paroxismal reactions of the scalp].
Topics: Acute Disease; Adult; Alopecia; Dermatitis, Seborrheic; Female; Humans; Lice Infestations; Male; Pos | 2004 |
The itchy patient. A practical approach.
Topics: Cholestasis; Drug-Related Side Effects and Adverse Reactions; Endocrine System Diseases; Female; Hem | 1983 |
14 trials available for salicylic acid and Pruritus
Article | Year |
---|---|
Maintenance effect of a once-weekly regimen of a Selenium Disulfide-based shampoo in moderate-to-severe scalp seborrheic dermatitis after initial treatment with topical corticosteroid/salicylic acid.
Topics: Adrenal Cortex Hormones; Adult; Dandruff; Dermatitis, Seborrheic; Double-Blind Method; Humans; Pruri | 2023 |
Randomized trial comparing a chemical peel containing a lipophilic hydroxy acid derivative of salicylic acid with a salicylic acid peel in subjects with comedonal acne.
Topics: Acne Vulgaris; Administration, Topical; Adult; Chemexfoliation; Erythema; Face; Female; Humans; Kera | 2011 |
Single-center, open-label study of a proprietary topical 0.5% salicylic acid-based treatment regimen containing sandalwood oil in adolescents and adults with mild to moderate acne.
Topics: Acne Vulgaris; Administration, Topical; Adolescent; Adult; Drug Combinations; Endpoint Determination | 2012 |
Calcipotriol solution for the treatment of scalp psoriasis: evaluation of efficacy, safety and acceptance in 3,396 patients.
Topics: Adult; Calcitriol; Cohort Studies; Combined Modality Therapy; Dermatologic Agents; Drug Therapy, Com | 2001 |
Saccharide isomerate ameliorates cosmetic scalp conditions in a Chinese study population.
Topics: Adult; Dandruff; Humans; Pruritus; Scalp; Skin | 2023 |
TRPM8 agonist (cryosim-1) gel for scalp itch: a randomised, vehicle-controlled clinical trial.
Topics: Humans; Membrane Proteins; Pruritus; Scalp; TRPM Cation Channels | 2022 |
Clinical evaluation of paraprobiotic-associated Bifidobacterium lactis CCT 7858 anti-dandruff shampoo efficacy: A randomized placebo-controlled clinical trial.
Topics: Bifidobacterium animalis; Dandruff; Hair Preparations; Humans; Pruritus; Scalp; Skin | 2023 |
Pharmacokinetics of ingenol mebutate gel under maximum use conditions in large treatment areas.
Topics: Administration, Cutaneous; Aged; Aged, 80 and over; Area Under Curve; Arm; Diterpenes; Face; Female; | 2018 |
Safety and Efficacy of Escalating Doses of Ingenol Mebutate for Field Treatment of Actinic Keratosis on the Full Face, Full Balding Scalp, or Chest.
Topics: Administration, Topical; Aged; Diterpenes; Dose-Response Relationship, Drug; Face; Female; Humans; K | 2017 |
Secukinumab improves scalp pain, itching, scaling and quality of life in patients with moderate-to-severe scalp psoriasis.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Double-Blind Method; Female; Human | 2017 |
Efficacy of a new tonic containing urea, lactate, polidocanol, and glycyrrhiza inflata root extract in the treatment of a dry, itchy, and subclinically inflamed scalp.
Topics: Chalcones; Cytokines; Glycyrrhiza; Humans; Lactic Acid; Lipid Metabolism; Plant Extracts; Plant Root | 2013 |
Scalp stratum corneum histamine levels: novel sampling method reveals association with itch resolution in dandruff/seborrhoeic dermatitis treatment.
Topics: Administration, Topical; Adult; Analysis of Variance; Antipruritics; Biomarkers; Chromatography, Hig | 2011 |
Assessment of the safety and efficacy of three concentrations of topical ivermectin lotion as a treatment for head lice infestation.
Topics: Administration, Topical; Adolescent; Adult; Animals; Child; Child, Preschool; Dose-Response Relation | 2013 |
A national double-blind clinical trial of a new corticosteroid lotion: a 12-investigator cooperative analysis.
Topics: 1-Propanol; Adolescent; Adult; Aged; Betamethasone; Child; Child, Preschool; Clinical Trials as Topi | 1972 |
43 other studies available for salicylic acid and Pruritus
Article | Year |
---|---|
The effect of topically applied salicylic compounds on serotonin-induced scratching behaviour in hairless rats.
Topics: Administration, Topical; Animals; Antipruritics; Female; Pruritus; Rats; Rats, Mutant Strains; Salic | 2002 |
SEBORRHEA, SEBORRHEIC DERMATITIS AND THE SEBORRHEID REACTION.
Topics: Adrenal Cortex Hormones; Child; Clioquinol; Coal Tar; Dermatitis; Dermatitis, Seborrheic; Dermatolog | 1964 |
[A new type of treatment of pruritic dermatoses].
Topics: Dermatology; Humans; Pruritus; Salicylic Acid; Skin Diseases | 1961 |
Pruritus: Diagnosis and Management.
Topics: Administration, Topical; Adrenal Cortex Hormones; Aged; Blood Cell Count; Blood Sedimentation; Blood | 2022 |
Localized alopecia with itching on the scalp.
Topics: Alopecia; Dermoscopy; Diagnosis, Differential; Humans; Pruritus; Scalp; Scalp Dermatoses | 2022 |
Microbiota profiling on itchy scalp with undetermined origin.
Topics: Female; Humans; Microbiota; Pruritus; RNA, Ribosomal, 16S; Scalp; Skin | 2022 |
Prospective Observational Evaluation of Fixed Combination Calcipotriol/Betamethasone Aerosol Foam (Enstilar®) in the Management of Psoriasis with Scalp Involvement in Everyday Clinical Practice (the CAPITIS Study).
Topics: Adult; Aerosols; Betamethasone; Dermatologic Agents; Drug Combinations; Humans; Prospective Studies; | 2023 |
Persistent itching of the eyelids and scalp.
Topics: Eyelids; Humans; Pruritus; Scalp | 2022 |
Neuroimmune Mediators of Pruritus in Hispanic Scalp Psoriatic Itch.
Topics: Hispanic or Latino; Humans; Pruritus; Psoriasis; Scalp; Substance P | 2023 |
Alopecia in Patients with Collagen VI-Related Myopathies: A Novel/Unrecognized Scalp Phenotype.
Topics: Alopecia; Collagen; Folliculitis; Humans; Muscular Diseases; Phenotype; Pruritus; Scalp | 2023 |
Treatment of scalp dysesthesia utilising simple exercises and stretches: A pilot study.
Topics: Adolescent; Adult; Aged; Cervical Vertebrae; Exercise Therapy; Female; Humans; Male; Middle Aged; Mu | 2018 |
Trichostasis spinulosa arising in isolated collagenoma of the scalp.
Topics: Alopecia; Child; Female; Hair Diseases; Head and Neck Neoplasms; Humans; Keratosis; Nevus; Pruritus; | 2018 |
A Lesion on the Scalp.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Head and Neck Neoplasms; Humans; Lymphoma, Fol | 2019 |
Qualitative analysis and reproducibility assessment of the Scalp Itch Numeric Rating Scale among patients with moderate to severe plaque psoriasis of the scalp.
Topics: Adult; Aged; Cross-Sectional Studies; Female; Humans; Interviews as Topic; Male; Middle Aged; Prurit | 2019 |
Qualitative analysis and reproducibility assessment of the Scalp Itch Numeric Rating Scale among patients with moderate to severe plaque psoriasis of the scalp.
Topics: Adult; Aged; Cross-Sectional Studies; Female; Humans; Interviews as Topic; Male; Middle Aged; Prurit | 2019 |
Qualitative analysis and reproducibility assessment of the Scalp Itch Numeric Rating Scale among patients with moderate to severe plaque psoriasis of the scalp.
Topics: Adult; Aged; Cross-Sectional Studies; Female; Humans; Interviews as Topic; Male; Middle Aged; Prurit | 2019 |
Qualitative analysis and reproducibility assessment of the Scalp Itch Numeric Rating Scale among patients with moderate to severe plaque psoriasis of the scalp.
Topics: Adult; Aged; Cross-Sectional Studies; Female; Humans; Interviews as Topic; Male; Middle Aged; Prurit | 2019 |
Refractory Cutaneous Dermatomyositis With Severe Scalp Pruritus Responsive to Apremilast.
Topics: Dermatomyositis; Female; Humans; Immunomodulating Agents; Immunosuppressive Agents; Pruritus; Scalp; | 2021 |
Evaluation of factors triggering sensitive scalp in Korean adult women.
Topics: Adult; Body Temperature; Female; Humans; Middle Aged; Pruritus; Republic of Korea; Scalp; Skin Disea | 2019 |
Women with scalp dysesthesia treated with pregabalin.
Topics: Adult; Analgesics; Female; gamma-Aminobutyric Acid; Humans; Pain; Paresthesia; Pregabalin; Pruritus; | 2013 |
Clinical and histopathological features of itch in patients with alopecia areata.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alopecia Areata; Arachidonate 5-Lipoxygenase; Biopsy; Ca | 2013 |
Severe facial swelling in a pregnant woman after using hair dye.
Topics: Adult; Edema; Face; Female; Hair Dyes; Humans; Hypersensitivity, Delayed; Pregnancy; Pregnancy Compl | 2014 |
Trigeminal trophic syndrome with histopathologic correlation.
Topics: Biopsy; Female; Herpes Zoster; Humans; Middle Aged; Nasal Cavity; Pain; Pruritus; Scalp; Syndrome; T | 2015 |
Cronkhite-Canada syndrome: A rare disease presenting with dermatological and gastrointestinal manifestations.
Topics: Abdominal Pain; Aged; Alopecia; Anorexia; Diarrhea; Female; Humans; Intestinal Polyposis; Lethargy; | 2016 |
Acute alopecia with underlying pruritic erythema.
Topics: Adult; Alopecia; Erythema; Facial Dermatoses; Facial Neoplasms; Forehead; Head and Neck Neoplasms; H | 2015 |
Multiple eruptive milia on scalp.
Topics: Adolescent; Aged; Child; Child, Preschool; Female; Humans; Keratosis; Male; Middle Aged; Pruritus; S | 2016 |
Tick Bite Alopecia: A Report and Review.
Topics: Adolescent; Alopecia; Biopsy; Child; Child, Preschool; Female; Humans; Male; Mucinosis, Follicular; | 2016 |
Physiological and microbiological verification of the benefit of hair washing in patients with skin conditions of the scalp.
Topics: Adult; Aged; Anti-Bacterial Agents; Bacteria; Dermatitis, Seborrheic; DNA, Bacterial; DNA, Fungal; E | 2016 |
Efficacy and safety of superficial cryotherapy for alopecia areata: A retrospective, comprehensive review of 353 cases over 22 years.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alopecia Areata; Child; Child, Preschool; Cryotherapy; F | 2017 |
Pruritic papules on the scalp and arms.
Topics: Arm; Hair Follicle; Humans; Male; Middle Aged; Mycosis Fungoides; Pruritus; Scalp; Skin Neoplasms | 2016 |
The itchy scalp.
Topics: Humans; Pruritus; Scalp; Scalp Dermatoses | 2017 |
Frontal fibrosing alopecia: a clinical review of 36 patients.
Topics: Adult; Aged; Aged, 80 and over; Alopecia; Anti-Bacterial Agents; Cohort Studies; Dermatologic Agents | 2010 |
Aberrant C nerve fibre function of the healthy scalp.
Topics: Adult; Female; Hot Temperature; Humans; Male; Middle Aged; Nerve Fibers, Unmyelinated; Pain; Pain Th | 2012 |
A pediculid case: autosensitization dermatitis caused by pediculosis capitis.
Topics: Aged; Animals; Dermatitis; Exanthema; Female; Hair; Humans; Lice Infestations; Lymphatic Diseases; P | 2012 |
Dandruff: a condition characterized by decreased levels of intercellular lipids in scalp stratum corneum and impaired barrier function.
Topics: Administration, Cutaneous; Adult; Case-Control Studies; Cholesterol; Dermatitis, Seborrheic; Epiderm | 2002 |
Sensitivity of human scalp skin to pruritic stimuli investigated by intradermal microdialysis in vivo.
Topics: Adult; Forearm; Histamine; Humans; Male; Microdialysis; p-Methoxy-N-methylphenethylamine; Pruritus; | 2002 |
Pseudo-delusory syndrome caused by Limothrips cerealium.
Topics: Agricultural Workers' Diseases; Animals; Delusions; Diagnostic Errors; Ectoparasitic Infestations; E | 2006 |
Successful treatment of recalcitrant necrotizing eosinophilic folliculitis using indomethacin and cephalexin.
Topics: Administration, Oral; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Cephalexin; Di | 2006 |
Pediculid. An unusual -id reaction to pediculosis capitis.
Topics: Adult; Child, Preschool; Exanthema; Extremities; Female; Humans; Hypersensitivity; Lice Infestations | 1984 |
Fiber implantation for pattern baldness. Review of complications in forty-one patients.
Topics: Acrylates; Adult; Alopecia; Cicatrix; Edema; Female; Foreign-Body Reaction; Hair; Humans; Male; Post | 1981 |
Surgical treatment of fiber-implanted scalps.
Topics: Acrylic Resins; Adult; Humans; Male; Middle Aged; Polyvinyl Chloride; Prostheses and Implants; Pruri | 1981 |
Scalp psoriasis, clinical presentations and therapeutic management.
Topics: Administration, Topical; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Child | 1998 |
Pityriasis amiantacea.
Topics: Alopecia; Child; Diagnosis, Differential; Elbow; Female; Humans; Pityriasis; Pruritus; Scalp | 1999 |
[Eosinophilic arteritis of the scalp].
Topics: Adult; Arteritis; Biopsy; Diagnosis, Differential; Eosinophilia; Female; Humans; Pruritus; Remission | 2001 |
Diabetes and pruritus of the scalp.
Topics: Diabetes Complications; Humans; Pruritus; Scalp | 1977 |
Forehead rhytidoplasty and brow lifting.
Topics: Alopecia; Dermabrasion; Eyebrows; Face; Female; Hematoma; Humans; Male; Postoperative Complications; | 1976 |